## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2020-04-08_Virtual Town Hall 3_fixnames.md
last updated: 2024-12-31 Created QA Sections
link pdf: https://www.fda.gov/media/136833/download?attachment
link youtube: https://youtu.be/qpmRhUgrfTA
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Guidance on COVID-19 Testing and Validation Procedures

QA Block 1-1
CLARIFIED QUESTION: Are developers required to validate alternate supplies and reagents such as alternate viral transport media, swabs, or PCR instruments?
CLARIFIED ANSWER: Laboratories with EUA authorization or submissions can validate alternate supplies or reagents via a bridging study without submitting further to the FDA. However, manufacturers making alterations to their products must validate and submit their changes to the FDA.
VERBATIM QUESTION: Are developers required to validate alternate supplies and reagents such as alternate viral transport media, swabs, or PCR instruments?
VERBATIM ANSWER: If you are a holder of an EUA authorization or have submitted an EUA and you're a laboratory you can simply do a bridging study with the alternate reagent or supply validate it to your standards into clear standards and then you can begin using that. You do not need to submit an amendment or an application to the FDA. If you are using someone else's EUA authorized device you could do the same thing without submitting if you're a laboratory submit - and submit that you don't have to if you're a laboratory you don't need to submit anything to the FDA. However in both situations we would love to see the validation instrument validation data that you generated in order that it might be helpful to others and with your position would like to add that alternate supplier reagent on to our Frequently Asked questions page. So it's not required to submit your data but we would love to see it. If you are a test manufacture and you have an alteration to your product yes that does require validation and it does require a submission to the FDA usually in the form of a supplement and we also work closely with you to address those additions as quickly as possible to make more options available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA Validation, Alternate Supplies, FDA Submission Requirements
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is required from test manufacturers when they make alterations to their products?
CLARIFIED ANSWER: Test manufacturers making alterations to their products must validate the changes and submit them to the FDA, typically as a supplement. The FDA works with manufacturers to address these updates quickly to expand available options.
VERBATIM QUESTION: What is required from test manufacturers when they make alterations to their products?
VERBATIM ANSWER: If you are a test manufacture and you have an alteration to your product yes that does require validation and it does require a submission to the FDA usually in the form of a supplement and we also work closely with you to address those additions as quickly as possible to make more options available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test alterations, FDA submission requirements, product validation
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: Is home collection or home testing allowed, and what is necessary to pursue this pathway?
CLARIFIED ANSWER: Home collection or home testing requires an EUA authorization. Interested developers should contact the FDA to design studies ensuring safety, accuracy, and proper shipping validation. The FDA encourages these efforts and is working with developers on approvals.
VERBATIM QUESTION: Is home collection or home testing allowed, and what is necessary to pursue this pathway?
VERBATIM ANSWER: Next set of questions that are recurring have to do with whether or not home collection is allowed and we have said that collection and/or home testing require a UA authorization. So if you are interested in this pathway please reach out to us at our general EUA address and we'll work with you to design the appropriate studies to ensure that home collection is safe and is accurate and that the shipping return to the laboratory is also considered and is validated so that we know that when the samples are returned to the laboratory accurate results are obtained and false negatives are avoided. So we do welcome these. We do encourage these however we have stated that any EUA authorization is required. We are working with a number of developers now and hope to have some positive news in the near future with these amendments or these authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, home testing, home collection
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: Who can laboratories or developers contact regarding the design of studies for home collection to ensure safety and accuracy?
CLARIFIED ANSWER: Laboratories or developers can contact the FDA through their general EUA address to receive guidance on designing studies for home collection to ensure safety and accuracy.
VERBATIM QUESTION: Who can laboratories or developers contact regarding the design of studies for home collection to ensure safety and accuracy?
VERBATIM ANSWER: Next set of questions that are recurring have to do with whether or not home collection is allowed and we have said that collection and/or home testing require a UA authorization. So if you are interested in this pathway please reach out to us at our general EUA address and we'll work with you to design the appropriate studies to ensure that home collection is safe and is accurate and that the shipping return to the laboratory is also considered and is validated so that we know that when the samples are returned to the laboratory accurate results are obtained and false negatives are avoided.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home collection, Safety, EUA contact
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How soon can developers expect to hear back after submitting an EUA application?
CLARIFIED ANSWER: Developers can contact the general EUA address or their assigned reviewer for updates on their EUA application status. FDA prioritizes applications that need immediate attention.
VERBATIM QUESTION: How soon can developers expect to hear back after submitting an EUA application?
VERBATIM ANSWER: We generally get a number of questions about when you hear back after you have submitted your EUA. If you are allowed be on the market with your test and do not require an EUA authorization before you can test in the way that you want we are triaging those that need our immediate attention. You can always reach out to us through the general EUA address or to - if you're going to sign the reviewer to reach out to your reviewer to get an update about where you stand.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA application response time, FDA contact for EUA updates
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: Should validation data be sent to the authorized state or to the FDA if a state is reviewing the tests?
CLARIFIED ANSWER: Validation data can be sent to the state if it is authorized to review tests, but submissions to the FDA are always welcome.
VERBATIM QUESTION: Should validation data be sent to the authorized state or to the FDA if a state is reviewing the tests?
VERBATIM ANSWER: Of course even if your state is willing to authorize tests within your state you are always welcome to submit an EUA application to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation data submission, State review, FDA EUA application
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: What information or organizations are involved in the FDA partnership for 3-D printing and additive manufacturing efforts to address supply chain issues?
CLARIFIED ANSWER: The FDA has partnered with the Department of Veterans Affairs and the NIH 3-D print exchange under an MOU to share data and coordinate on open-source medical products for the COVID-19 response. The FDA also engages other stakeholders to enhance 3-D printing and manufacturing efforts.
VERBATIM QUESTION: What information or organizations are involved in the FDA partnership for 3-D printing and additive manufacturing efforts to address supply chain issues?
VERBATIM ANSWER: FDA has recognized that many stakeholders are interested in designing and producing 3-D printer devices and other types of and devices that are made through other nontraditional manufacturing methods as well. So what we have done to try to accept different input from the community is form a partnership under an MOU with the Department of Veterans Affairs innovation ecosystem and the NIH 3-D print exchange to share data and coordinate on open source medical products for the COVID-19 response. So these agencies were working with closely as well with American made supervise resources that will help connect healthcare providers and 3-D printing organizations. So we already have an FDA Q&A that's available on our Web site for 3-D printed medical devices including PPE, decontamination and reuse of respirators information, optimizing respirator decontamination and so on and so forth.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: FDA partnerships, 3-D printing, Supply chain issues
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: How can academic institutions contribute to addressing both local and national shortages?
CLARIFIED ANSWER: Academic institutions are engaging in efforts to address local and national shortages by contributing expertise and resources. The FDA is in dialogue with organizations such as AAMCA, AAU, and APLU to coordinate efforts across the university system.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: There is a growing number of institutions from academic sector including universities and academic medical centers who are interested in contributing personnel expertise, resources and other things at their disposal across the country to try to address both local and national shortages. So we've engaged in dialogue at this point with the AAMCA AAU and APLU with regards to how we can all work together collectively across the university system as well to help address emerging challenges.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: academic institutions, resource shortages, collaboration
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: What are the specific accuracy concerns associated with serology tests, and how does the FDA plan to address them?
CLARIFIED ANSWER: The FDA has expressed concerns about serology test accuracy and is establishing a voluntary interagency program. This program will independently assess performance using test kits, necessary instrumentation, and panels of positive and negative samples.
VERBATIM QUESTION: What are the specific accuracy concerns associated with serology tests, and how does the FDA plan to address them?
VERBATIM ANSWER: There has been some concern about the accuracy of some of these tests. And so the FDA in collaboration with other agencies is standing up a volunteer - a voluntary interagency program to help address and verify error accuracy. Developers involuntarily participate in this program. They can send their point of care test kits and any instrumentation that might be needed to a central location. And we are putting together a panel of positive sera and plasma and negative serum plasma in order to take a look at performance of these tests through an independent assessment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test accuracy, FDA validation efforts, Independent assessment program
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: How can developers participate in the voluntary interagency accuracy verification program for serology tests?
CLARIFIED ANSWER: Developers can participate in the voluntary interagency accuracy verification program for serology tests by emailing the general EUA address at cdrh-eua-templates@fda.hhs.gov.
VERBATIM QUESTION: How can developers participate in the voluntary interagency accuracy verification program for serology tests?
VERBATIM ANSWER: If you are a developer and are interested in this program please send an email to our general EUA address. That is cdrh-eua-templates with an S @fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: voluntary accuracy program, serology tests participation, EUA email address
REVIEW FLAG: False

QA Block 1-14
CLARIFIED QUESTION: What is the process for notifying the FDA about completing validation for serology tests under Pathway D?
CLARIFIED ANSWER: Developers complete validation for serology tests under Pathway D, notify the FDA, and after exchanges to ensure guidance is followed, they receive confirmation to market the tests in the US.
VERBATIM QUESTION: What is the process for notifying the FDA about completing validation for serology tests under Pathway D?
VERBATIM ANSWER: Many have come through the Pathway D where they notify the FDA that they have completed validation and then once there is a few exchanges to understand that everything is being addressed according to the guidance then those developers are - receive a confirmation message and are able to market in the US.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation process, Serology tests, FDA notification
REVIEW FLAG: False

QA Block 1-15
CLARIFIED QUESTION: What type of data should developers provide to the FDA when voluntarily submitting validation data for alternate reagents or supplies?
CLARIFIED ANSWER: Developers should provide validation data they generated for alternate reagents or supplies. While submission is not required, the FDA encourages it to potentially assist others and update FAQs.
VERBATIM QUESTION: What type of data should developers provide to the FDA when voluntarily submitting validation data for alternate reagents or supplies?
VERBATIM ANSWER: So if you are a holder of an EUA authorization or have submitted an EUA and you're a laboratory you can simply do a bridging study with the alternate reagent or supply validate it to your standards into clear standards and then you can begin using that. You do not need to submit an amendment or an application to the FDA. However in both situations we would love to see the validation instrument validation data that you generated in order that it might be helpful to others and with your position would like to add that alternate supplier reagent on to our Frequently Asked questions page. So it's not required to submit your data but we would love to see it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation data submission, Alternate reagents or supplies, FDA recommendations
REVIEW FLAG: False

QA Block 1-16
CLARIFIED QUESTION: Are developers required to use a specific format when submitting validation data to the FDA?
CLARIFIED ANSWER: Developers are not required to submit validation data unless they are making alterations to a product, which would require a validation submission in the form of a supplement to the FDA.
VERBATIM QUESTION: Are developers required to use a specific format when submitting validation data to the FDA?
VERBATIM ANSWER: It's not required to submit your data but we would love to see it. If you are a test manufacture and you have an alteration to your product yes that does require validation and it does require a submission to the FDA usually in the form of a supplement and we also work closely with you to address those additions as quickly as possible to make more options available.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation Data Submission, FDA Requirements
REVIEW FLAG: False

QA Block 1-17
CLARIFIED QUESTION: What is the FDA's process for independent assessment of the performance of serology tests?
CLARIFIED ANSWER: The FDA has created a voluntary interagency program for independent assessment of serology test performance. Developers can submit test kits and necessary instruments to a central location for evaluation using positive and negative sera and plasma.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And so the FDA in collaboration with other agencies is standing up a volunteer - a voluntary interagency program to help address and verify error accuracy. Developers involuntarily participate in this program. They can send their point of care test kits and any instrumentation that might be needed to a central location. And we are putting together a panel of positive sera and plasma and negative serum plasma in order to take a look at performance of these tests through an independent assessment. If you are a developer and are interested in this program please send an email to our general EUA address. That is cdrh-eua-templates with an S @fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test performance assessment, Independent evaluation, Voluntary FDA program
REVIEW FLAG: False

QA Block 1-18
CLARIFIED QUESTION: Does participation in the voluntary interagency program for accuracy testing have any impact on EUA applications or market authorization?
CLARIFIED ANSWER: Participation in the voluntary interagency program involves independent accuracy assessment of test kits by FDA and does not directly impact EUA applications or market authorization.
VERBATIM QUESTION: Does participation in the voluntary interagency program for accuracy testing have any impact on EUA applications or market authorization?
VERBATIM ANSWER: Developers involuntarily participate in this program. They can send their point of care test kits and any instrumentation that might be needed to a central location. And we are putting together a panel of positive sera and plasma and negative serum plasma in order to take a look at performance of these tests through an independent assessment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Voluntary interagency program, Test accuracy verification
REVIEW FLAG: False

QA Block 1-19
CLARIFIED QUESTION: When will the FDA provide additional updates regarding approvals for home collection and home testing pathways?
CLARIFIED ANSWER: The FDA is working on EUA authorizations for home collection and home testing and hopes to provide positive updates in the near future. Developers can contact the FDA for guidance on designing studies for safety and accuracy.
VERBATIM QUESTION: When will the FDA provide additional updates regarding approvals for home collection and home testing pathways?
VERBATIM ANSWER: Next set of questions that are recurring have to do with whether or not home collection is allowed and we have said that collection and/or home testing require a UA authorization. So if you are interested in this pathway please reach out to us at our general EUA address and we'll work with you to design the appropriate studies to ensure that home collection is safe and is accurate and that the shipping return to the laboratory is also considered and is validated so that we know that when the samples are returned to the laboratory accurate results are obtained and false negatives are avoided. So we do welcome these. We do encourage these however we have stated that any EUA authorization is required. We are working with a number of developers now and hope to have some positive news in the near future with these amendments or these authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorizations, Home collection/testing, Update timelines
REVIEW FLAG: False


#### 2. Guidance on Pre-EUA Submissions for Serology Kit Validation

QA Block 2-1
CLARIFIED QUESTION: Should a manufacturer using Policy C for EUA of a serology kit with incomplete initial validation data engage in pre-EUA conversations with the FDA to understand additional data requirements?
CLARIFIED ANSWER: Manufacturers can either submit a complete application for review or engage in pre-EUA discussions to determine additional data needs. The FDA will assist based on the chosen pathway.
VERBATIM QUESTION: Should a manufacturer using Policy C for EUA of a serology kit with incomplete initial validation data engage in pre-EUA conversations with the FDA to understand additional data requirements?
VERBATIM ANSWER: Well if they think they have a complete application they can put in a submission using the - I guess we don't have a template but if you send - if they send in an email to our general EUA templates we do have a fact sheet that we can provide to them. But if you do think you have a complete submission you can make a submission to our - to the submission email and we will all take a look at it and if there's anything missing we can look at - we can reach out back out to the developer. On the other hand you'll also are able to do that through the pre-EUA. So whatever pathway you think is most efficient for you we'll work with you on that.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy C for EUA, serology kit validation, pre-EUA discussions
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What is the process for obtaining a fact sheet for submissions under Policy C?
CLARIFIED ANSWER: To obtain a fact sheet under Policy C, you can email the FDA's general EUA templates email, and they will provide it.
VERBATIM QUESTION: What is the process for obtaining a fact sheet for submissions under Policy C?
VERBATIM ANSWER: If they send in an email to our general EUA templates we do have a fact sheet that we can provide to them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy C submission, Fact sheet, EUA process
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Can a submission with incomplete initial validation data proceed without pre-EUA discussions?
CLARIFIED ANSWER: FDA recommends submitting either a complete submission directly or conducting pre-EUA discussions. If any data is missing from a submission, FDA will follow up with the developer.
VERBATIM QUESTION: Can a submission with incomplete initial validation data proceed without pre-EUA discussions?
VERBATIM ANSWER: Well if they think they have a complete application they can put in a submission using the - I guess we don't have a template but if you send - if they send in an email to our general EUA templates we do have a fact sheet that we can provide to them. But if you do think you have a complete submission you can make a submission to our - to the submission email and we will all take a look at it and if there's anything missing we can look at - we can reach out back out to the developer. On the other hand you'll also are able to do that through the pre-EUA. So whatever pathway you think is most efficient for you we'll work with you on that.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission process, Pre-EUA discussions, Validation data requirements
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Which pathway, pre-EUA or direct submission, does the FDA recommend for a more efficient review process?
CLARIFIED ANSWER: FDA suggests using either direct submission or the pre-EUA pathway based on what is most efficient for the manufacturer.
VERBATIM QUESTION: Which pathway, pre-EUA or direct submission, does the FDA recommend for a more efficient review process?
VERBATIM ANSWER: But if you do think you have a complete submission you can make a submission to our - to the submission email and we will all take a look at it and if there's anything missing we can look at - we can reach out back out to the developer. On the other hand you'll also are able to do that through the pre-EUA. So whatever pathway you think is most efficient for you we'll work with you on that.
SPEAKER QUESTION: Daniel Simpson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission pathways, pre-EUA consultations
REVIEW FLAG: False


#### 3. Guidance on Alternate Sample Types and Authorization Requirements

QA Block 3-1
CLARIFIED QUESTION: If we are looking at alternate sample types, will a bridging study suffice or do we need to design an appropriate study with FDA guidance?
CLARIFIED ANSWER: For alternate sample types not previously authorized, the FDA requires collaboration to design an appropriate study. If the sample type is already authorized, a bridging study is enough, and no submission to the FDA is needed.
VERBATIM QUESTION: If we are looking at alternate sample types, will a bridging study suffice or do we need to design an appropriate study with FDA guidance?
VERBATIM ANSWER: Yes that's a great question. So for any sample type that we've already authorized so whether it be NP swab, mid-turbinate, mid-turbinate self- collected and then healthcare increment nasal swab or a self-collected nasal swab in the healthcare environment nasopharyngeal swab or sputum I believe that's a complete list of what we've authorized so far. We have seen some data with regard to a tongue swab and there are interested parties in saliva. Some of these alternate samples may not perform as well as others so at this time yes we would like to engage on - with the developer on an alternate sample type if it's not one of the ones that we've already authorized. If we've already authorized that sample type and you simply want to say switch swabs that's something that you can perform your own bridging study if you're it LDT developer or if you're altering an EUA authorized test and you don't need to submit that to the FDA.
SPEAKER QUESTION: Heather
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternate sample types, bridging study, FDA guidance
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What is the complete list of sample types currently authorized by the FDA for COVID-19 diagnostic tests?
CLARIFIED ANSWER: The FDA has authorized NP swabs, mid-turbinate swabs (self-collected), healthcare-supervised nasal swabs, self-collected nasal swabs, nasopharyngeal swabs, and sputum for COVID-19 diagnostic testing.
VERBATIM QUESTION: What is the complete list of sample types currently authorized by the FDA for COVID-19 diagnostic tests?
VERBATIM ANSWER: So for any sample type that we've already authorized so whether it be NP swab, mid-turbinate, mid-turbinate self-collected and then healthcare increment nasal swab or a self-collected nasal swab in the healthcare environment nasopharyngeal swab or sputum I believe that's a complete list of what we've authorized so far.
SPEAKER QUESTION: Heather
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Authorized sample types, COVID-19 diagnostic tests
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Does the FDA require engagement with developers for alternate sample types that are not already authorized?
CLARIFIED ANSWER: Yes, the FDA requires developers to engage with them for alternate sample types that are not already authorized.
VERBATIM QUESTION: Does the FDA require engagement with developers for alternate sample types that are not already authorized?
VERBATIM ANSWER: So for any sample type that we've already authorized so whether it be NP swab, mid-turbinate, mid-turbinate self- collected and then healthcare increment nasal swab or a self-collected nasal swab in the healthcare environment nasopharyngeal swab or sputum I believe that's a complete list of what we've authorized so far. We have seen some data with regard to a tongue swab and there are interested parties in saliva. Some of these alternate samples may not perform as well as others so at this time yes we would like to engage on - with the developer on an alternate sample type if it's not one of the ones that we've already authorized.
SPEAKER QUESTION: Heather
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: alternate sample types, developer engagement, FDA authorization
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What kind of data has the FDA reviewed regarding tongue swabs and saliva as alternate sample types?
CLARIFIED ANSWER: The FDA has reviewed some data on tongue swabs and is aware of interest in saliva, but these samples may not perform as well as authorized ones. Developers need FDA engagement for unapproved alternate sample types.
VERBATIM QUESTION: What kind of data has the FDA reviewed regarding tongue swabs and saliva as alternate sample types?
VERBATIM ANSWER: We have seen some data with regard to a tongue swab and there are interested parties in saliva. Some of these alternate samples may not perform as well as others so at this time yes we would like to engage on - with the developer on an alternate sample type if it's not one of the ones that we've already authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: tongue swabs, saliva, alternate sample types
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: Can developers perform their own bridging study for switching swabs, and under what circumstances is this permissible?
CLARIFIED ANSWER: Developers can perform their own bridging study for switching swabs if the sample type has already been authorized, and they are an LDT developer or modifying an EUA-authorized test. Submission to the FDA is not needed in this case.
VERBATIM QUESTION: Can developers perform their own bridging study for switching swabs, and under what circumstances is this permissible?
VERBATIM ANSWER: If we've already authorized that sample type and you simply want to say switch swabs that's something that you can perform your own bridging study if you're it LDT developer or if you're altering an EUA authorized test and you don't need to submit that to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: bridging study, swab switching, developer guidelines
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: Is submission to the FDA required if an EUA-authorized test is altered using a different sample type?
CLARIFIED ANSWER: If the FDA has already authorized the sample type, switching swabs or altering an EUA-authorized test only requires a bridging study, and does not need submission to the FDA.
VERBATIM QUESTION: Is submission to the FDA required if an EUA-authorized test is altered using a different sample type?
VERBATIM ANSWER: If we've already authorized that sample type and you simply want to say switch swabs that's something that you can perform your own bridging study if you're it LDT developer or if you're altering an EUA authorized test and you don't need to submit that to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test modifications, Submission requirements, FDA authorization
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: What is the FDA's process for authorizing home collection or home testing for EUA platforms?
CLARIFIED ANSWER: The FDA requires authorization for home collection or home testing for EUA platforms, and developers working on such tests should engage with the agency.
VERBATIM QUESTION: What is the FDA's process for authorizing home collection or home testing for EUA platforms?
VERBATIM ANSWER: Okay, and of course if it's a home collection or a home testing if that's the kind of development work you do yes we also want to authorize those for the EUA platform in process.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection, home testing, EUA authorization
REVIEW FLAG: False


#### 4. Developing Tests Using RUO Instruments Under EUA Guidelines

QA Block 4-1
CLARIFIED QUESTION: Do CLIA laboratories need to utilize research-use-only (RUO) components for the development of their assays?
CLARIFIED ANSWER: Yes, CLIA laboratories can use RUO components to develop lab tests under emergency authorization and the FDA also works to validate RUO instruments for assay use in emergencies.
VERBATIM QUESTION: Do CLIA laboratories need to utilize research-use-only (RUO) components for the development of their assays?
VERBATIM ANSWER: Well that's a great question. Yes laboratories are able to utilize RUO components in their lab developed tests as RR manufacturers. Now typically - oh the excuse me, I'm going to put you on mute and cough. I just had a little allergy there I think. Typically outside of an emergency situation we would require more work for and an RUO instrument however under the emergency authorization Program we will work with developers, manufacturers to validate those instruments as well for use with their assays. Does that address your question?
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Use of RUO components, CLIA laboratory assay development, Emergency authorization validation
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Does the guidance on RUO components also apply to manufacturers and specifically to instruments?
CLARIFIED ANSWER: FDA confirmed that RUO components can be used by manufacturers, and under the emergency authorization program, RUO instruments can be validated for use with assays.
VERBATIM QUESTION: Does the guidance on RUO components also apply to manufacturers and specifically to instruments?
VERBATIM ANSWER: Well that's a great question. Yes laboratories are able to utilize RUO components in their lab developed tests as RR manufacturers. Now typically - oh the excuse me, I'm going to put you on mute and cough. I just had a little allergy there I think. Typically outside of an emergency situation we would require more work for and an RUO instrument however under the emergency authorization Program we will work with developers, manufacturers to validate those instruments as well for use with their assays. Does that address your question?
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO components, manufacturers, instrument validation
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Is it possible for kit manufacturers to develop kits for use with RUO instruments?
CLARIFIED ANSWER: Yes, under the emergency authorization program, manufacturers can validate RUO instruments for use with their assays, though typically outside emergencies more work is required for RUO instruments.
VERBATIM QUESTION: Is it possible for kit manufacturers to develop kits for use with RUO instruments?
VERBATIM ANSWER: Yes laboratories are able to utilize RUO components in their lab developed tests as RR manufacturers. Now typically - oh the excuse me, I'm going to put you on mute and cough. I just had a little allergy there I think. Typically outside of an emergency situation we would require more work for and an RUO instrument however under the emergency authorization Program we will work with developers, manufacturers to validate those instruments as well for use with their assays.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO instruments, Emergency Authorization Program, Test kit development
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Would manufacturers be able to develop a test and make it available while issuing an EUA within 15 days?
CLARIFIED ANSWER: Manufacturers can follow Pathway C, complete their validation, and submit their application within 15 business days. If everything checks out, it will be approved.
VERBATIM QUESTION: Would manufacturers be able to develop a test and make it available while issuing an EUA within 15 days?
VERBATIM ANSWER: They - that's a great question. Yes, they can follow Pathway C, complete their validation and then within 15 business days submit that application. And as long as everything looks good we're good.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA issuance process, Pathway C, validation timeline
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Would the FDA prefer to engage with manufacturers before an EUA issuance?
CLARIFIED ANSWER: Manufacturers can follow Pathway C, complete validation, and submit their EUA application within 15 business days, as long as all criteria are met.
VERBATIM QUESTION: Would the FDA prefer to engage with manufacturers before an EUA issuance?
VERBATIM ANSWER: They - that's a great question. Yes, they can follow Pathway C, complete their validation and then within 15 business days submit that application. And as long as everything looks good we're good.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA issuance process, Pathway C for manufacturers
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: Under the emergency authorization program, what validations are required for RUO instruments to be used with assays?
CLARIFIED ANSWER: Under the emergency authorization program, the FDA will work with developers and manufacturers to validate RUO instruments for use with their assays.
VERBATIM QUESTION: Under the emergency authorization program, what validations are required for RUO instruments to be used with assays?
VERBATIM ANSWER: Typically outside of an emergency situation we would require more work for and an RUO instrument however under the emergency authorization Program we will work with developers, manufacturers to validate those instruments as well for use with their assays.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO instrument validation, emergency authorization
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: What challenges might developers face when the EUA comes to an end, particularly regarding the use of RUO components?
CLARIFIED ANSWER: Developers should anticipate challenges after the EUA ends, such as the potential need for full submissions (e.g., de novo, 510K) for RUO instrumentation. FDA advises engaging with them to understand post-emergency pathways.
VERBATIM QUESTION: What challenges might developers face when the EUA comes to an end, particularly regarding the use of RUO components?
VERBATIM ANSWER: I would add though that there may be challenges once the EUA might come to an end. I don't expect that the emergency declaration will end anytime soon. However there is a provision in the EUA statues and regs that allows for specific technologies once they come through for a full authorization, normal authorization whether that's usually their de novo first and a 510K that there is an option for that particular type of device to be removed from the emergency declaration and require full submission. So as developers are developing this they should keep that in mind with regard to research use instrumentation but there may be a limit beyond an emergency in which they could use that other than labs that validate RUOs. They are potential pathways, it's just that it's good to talk to the FDA about those pathways ahead of time and be prepared for them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA challenges, RUO components, regulatory pathways
REVIEW FLAG: False

QA Block 4-8
CLARIFIED QUESTION: What are the pathways for transitioning RUO instruments to full authorization after the cessation of the emergency declaration?
CLARIFIED ANSWER: There are provisions in EUA statutes allowing specific technologies to transition to full authorization, such as de novo or 510(k) submissions, after the emergency ends. Developers should consult with the FDA early and be prepared for potential requirements.
VERBATIM QUESTION: What are the pathways for transitioning RUO instruments to full authorization after the cessation of the emergency declaration?
VERBATIM ANSWER: I would add though that there may be challenges once the EUA might come to an end. I don't expect that the emergency declaration will end anytime soon. However there is a provision in the EUA statues and regs that allows for specific technologies once they come through for a full authorization, normal authorization whether that's usually their de novo first and a 510K that there is an option for that particular type of device to be removed from the emergency declaration and require full submission. So as developers are developing this they should keep that in mind with regard to research use instrumentation but there may be a limit beyond an emergency in which they could use that other than labs that validate RUOs. They are potential pathways, it's just that it's good to talk to the FDA about those pathways ahead of time and be prepared for them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO instruments, EUA transition, full authorization
REVIEW FLAG: False

QA Block 4-9
CLARIFIED QUESTION: Does the FDA recommend developers prepare for full submission requirements for test components or instruments once the EUA ends?
CLARIFIED ANSWER: Developers should prepare for full submission requirements once the EUA ends. Certain technologies may need a normal authorization (e.g., de novo or 510(k)), and developers are advised to consult with the FDA and plan for this eventuality.
VERBATIM QUESTION: Does the FDA recommend developers prepare for full submission requirements for test components or instruments once the EUA ends?
VERBATIM ANSWER: I would add though that there may be challenges once the EUA might come to an end. I don't expect that the emergency declaration will end anytime soon. However there is a provision in the EUA statues and regs that allows for specific technologies once they come through for a full authorization, normal authorization whether that's usually their de novo first and a 510K that there is an option for that particular type of device to be removed from the emergency declaration and require full submission. So as developers are developing this they should keep that in mind with regard to research use instrumentation but there may be a limit beyond an emergency in which they could use that other than labs that validate RUOs. They are potential pathways, it's just that it's good to talk to the FDA about those pathways ahead of time and be prepared for them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test submissions post-EUA, Research Use Only (RUO) instruments, FDA authorization pathways
REVIEW FLAG: False

QA Block 4-10
CLARIFIED QUESTION: Are there specific provisions for technologies transitioning from EUA to traditional authorization pathways, such as de novo or 510(k) submissions?
CLARIFIED ANSWER: FDA notes that once an EUA ends, devices may transition to full traditional authorization pathways, such as de novo or 510(k). Developers should prepare for this by consulting with the FDA early on.
VERBATIM QUESTION: Are there specific provisions for technologies transitioning from EUA to traditional authorization pathways, such as de novo or 510(k) submissions?
VERBATIM ANSWER: I would add though that there may be challenges once the EUA might come to an end. I don't expect that the emergency declaration will end anytime soon. However there is a provision in the EUA statues and regs that allows for specific technologies once they come through for a full authorization, normal authorization whether that's usually their de novo first and a 510K that there is an option for that particular type of device to be removed from the emergency declaration and require full submission. So as developers are developing this they should keep that in mind with regard to research use instrumentation but there may be a limit beyond an emergency in which they could use that other than labs that validate RUOs. They are potential pathways, it's just that it's good to talk to the FDA about those pathways ahead of time and be prepared for them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA transition, traditional authorization pathways, de novo and 510(k) submissions
REVIEW FLAG: False


#### 5. CLIA Classification and Usage of Serology Tests

QA Block 5-1
CLARIFIED QUESTION: Can serology tests be used in labs with moderate complexity and a certificate under FDA guidance?
CLARIFIED ANSWER: FDA classifies all diagnostic tests as high complexity by default, unless authorized through the EUA process as moderately complex or CLIA-waived. While it's not intended to limit use to high-complexity labs, current regulations require this unless specific EUA authorization is granted. Developers can pursue EUA for CLIA-waived designation or participate in voluntary interagency verification programs.
VERBATIM QUESTION: Can serology tests be used in labs with moderate complexity and a certificate under FDA guidance?
VERBATIM ANSWER: Yes, that's a great question and it's a challenging question and a challenging answer. So under the EUA authorizations we are not making CLIA class CLIA classifications as far as high, moderate or waived. And also if we do not authorize through the EUA process a test we cannot deem something to be CLIA waived which is an alternate pathway under the EUA provision. So all tests are typically thought to be or assumed to be high complexity tests unless through the EUA authorization process we deem them as moderately complex or waived. This deeming is only something that's allowed under regs and statutes for tests that are authorized by the FDA. And so certainly it was not our intention to limit the use of these serology rapid serology tests that are otherwise designed to be used in a point-of-care setting. However because of the limits that we have in law it is the opinion of CMS that these can be performed in high complexity labs. If a developer wishes to come through a full EUA authorization process with their point-of-care test that is always a pathway open and at that point if the test is appropriate for a patient or a point-of-care setting we can deem that test to be that category and make that clear in the labeling and that then allows the device to be used in a near patient point-of-care setting. We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA classifications, Serology tests, EUA authorization
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: When will the template for EUA serology tests be available?
CLARIFIED ANSWER: You can request guidance via email, and the FDA is working on finalizing the template, which will be posted as soon as possible.
VERBATIM QUESTION: When will the template for EUA serology tests be available?
VERBATIM ANSWER: So you can send us an email request at our EUA CDRH EUA email and we can provide you with a document that lays out what we think is - are the studies that are recommended and the manner in which to do them.. We are working on a template and as soon as we can we will post that.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA serology test template, FDA guidance availability
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What steps can a developer take to get their point-of-care serology test deemed as moderately complex or waived?
CLARIFIED ANSWER: Developers can pursue full EUA authorization for their point-of-care serology test. If deemed appropriate for point-of-care use, the FDA will categorize it and clarify in labeling for near-patient settings. Exploring participation in interagency performance verification efforts may also help.
VERBATIM QUESTION: What steps can a developer take to get their point-of-care serology test deemed as moderately complex or waived?
VERBATIM ANSWER: If a developer wishes to come through a full EUA authorization process with their point-of-care test that is always a pathway open and at that point if the test is appropriate for a patient or a point-of-care setting we can deem that test to be that category and make that clear in the labeling and that then allows the device to be used in a near patient point-of-care setting. We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization for serology tests, CLIA categorization, FDA pathways for point-of-care testing
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: Does the FDA have any alternative pathways under evaluation to address the classification and use of serology tests in non-high complexity settings?
CLARIFIED ANSWER: The FDA is not making CLIA classifications (high, moderate, or waived) under EUA authorizations. Tests are assumed to be high complexity unless deemed otherwise via EUA authorization. There are alternative pathways being evaluated, including interagency efforts to verify test performance, which may enable reclassification. Developers are encouraged to participate in these voluntary programs.
VERBATIM QUESTION: Does the FDA have any alternative pathways under evaluation to address the classification and use of serology tests in non-high complexity settings?
VERBATIM ANSWER: Yes, that's a great question and it's a challenging question and a challenging answer. So under the EUA authorizations we are not making CLIA class CLIA classifications as far as high, moderate or waived. And also if we do not authorize through the EUA process a test we cannot deem something to be CLIA waived which is an alternate pathway under the EUA provision. So all tests are typically thought to be or assumed to be high complexity tests unless through the EUA authorization process we deem them as moderately complex or waived. This deeming is only something that's allowed under regs and statutes for tests that are authorized by the FDA. And so certainly it was not our intention to limit the use of these serology rapid serology tests that are otherwise designed to be used in a point-of-care setting. However because of the limits that we have in law it is the opinion of CMS that these can be performed in high complexity labs. If a developer wishes to come through a full EUA authorization process with their point-of-care test that is always a pathway open and at that point if the test is appropriate for a patient or a point-of-care setting we can deem that test to be that category and make that clear in the labeling and that then allows the device to be used in a near patient point-of-care setting. We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test classification, EUA process, Alternative evaluation pathways
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: How can developers participate in the interagency effort to verify the performance of serology tests?
CLARIFIED ANSWER: The FDA encourages serology point-of-care test developers to participate in a voluntary interagency program to verify the performance of these tests, which may offer a potential pathway.
VERBATIM QUESTION: How can developers participate in the interagency effort to verify the performance of serology tests?
VERBATIM ANSWER: I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test performance verification, Developer participation
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What implications does the CMS opinion have for the regulatory process of serology tests in high complexity labs?
CLARIFIED ANSWER: The FDA cannot deem serology tests as CLIA-waived unless authorized through the EUA process. By default, tests are high complexity unless deemed otherwise through the EUA. CMS's opinion allows these tests to be performed in high complexity labs, and developers can follow the EUA pathway to achieve moderate complexity or waived status.
VERBATIM QUESTION: What implications does the CMS opinion have for the regulatory process of serology tests in high complexity labs?
VERBATIM ANSWER: Yes, that's a great question and it's a challenging question and a challenging answer. So under the EUA authorizations we are not making CLIA class CLIA classifications as far as high, moderate or waived. And also if we do not authorize through the EUA process a test we cannot deem something to be CLIA waived which is an alternate pathway under the EUA provision. So all tests are typically thought to be or assumed to be high complexity tests unless through the EUA authorization process we deem them as moderately complex or waived. This deeming is only something that's allowed under regs and statutes for tests that are authorized by the FDA. And so certainly it was not our intention to limit the use of these serology rapid serology tests that are otherwise designed to be used in a point-of-care setting. However because of the limits that we have in law it is the opinion of CMS that these can be performed in high complexity labs. If a developer wishes to come through a full EUA authorization process with their point-of-care test that is always a pathway open and at that point if the test is appropriate for a patient or a point-of-care setting we can deem that test to be that category and make that clear in the labeling and that then allows the device to be used in a near patient point-of-care setting. We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CMS opinion on serology tests, Regulatory status for high complexity labs, EUA process for serology tests
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: Is it possible to expedite the EUA authorization process for point-of-care tests designed for non-high complexity settings?
CLARIFIED ANSWER: FDA clarifies that under EUA authorizations, tests are assumed high complexity unless explicitly authorized as moderately complex or waived. Developers may expedite point-of-care tests by completing the EUA process. FDA is exploring alternate interagency pathways to streamline this process.
VERBATIM QUESTION: Is it possible to expedite the EUA authorization process for point-of-care tests designed for non-high complexity settings?
VERBATIM ANSWER: Yes, that's a great question and it's a challenging question and a challenging answer. So under the EUA authorizations we are not making CLIA class CLIA classifications as far as high, moderate or waived. And also if we do not authorize through the EUA process a test we cannot deem something to be CLIA waived which is an alternate pathway under the EUA provision. So all tests are typically thought to be or assumed to be high complexity tests unless through the EUA authorization process we deem them as moderately complex or waived. This deeming is only something that's allowed under regs and statutes for tests that are authorized by the FDA. And so certainly it was not our intention to limit the use of these serology rapid serology tests that are otherwise designed to be used in a point-of-care setting. However because of the limits that we have in law it is the opinion of CMS that these can be performed in high complexity labs. If a developer wishes to come through a full EUA authorization process with their point-of-care test that is always a pathway open and at that point if the test is appropriate for a patient or a point-of-care setting we can deem that test to be that category and make that clear in the labeling and that then allows the device to be used in a near patient point-of-care setting. We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA process, Point-of-care test authorization, CLIA classifications
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: What specific performance measures or standards are being evaluated in the FDA's voluntary serology test verification program?
CLARIFIED ANSWER: The FDA is conducting an interagency effort to verify the performance of serology tests and is considering alternate pathways under the voluntary program, encouraging point-of-care test developers to participate.
VERBATIM QUESTION: What specific performance measures or standards are being evaluated in the FDA's voluntary serology test verification program?
VERBATIM ANSWER: We are looking at potential alternate pathways to achieve the same end. I mentioned that we have an interagency effort to verify performance of these tests. We may have a pathway open through that that we're looking at. And we encourage all serology point-of-care developers to participate. It's a voluntary program but that would be most helpful I think to everyone.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA serology test verification, voluntary program, test performance assessment
REVIEW FLAG: False


#### 6. Volunteering Opportunities for Industry Experts in Lab Collaboration

QA Block 6-1
CLARIFIED QUESTION: What is the best way for lab professionals in the industry to get involved in assisting with COVID-19 test selection, test validations, and electronic reporting?
CLARIFIED ANSWER: FDA suggests that interested lab professionals email Sara Brenner directly to discuss how to get involved in assisting with COVID-19 testing processes.
VERBATIM QUESTION: What is the best way for lab professionals in the industry to get involved in assisting with COVID-19 test selection, test validations, and electronic reporting?
VERBATIM ANSWER: Yes, that's great. And thank you Jeff for volunteering this information. It might be most expedient if you would shoot me an email and we can pick up the conversation from there. Sara, S-A-R-A.brenner, B as in Blue, R-E-N-N- E-R@fda.hhs.gov.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: involvement of industry lab professionals, COVID-19 test support, FDA contact channels
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Is there a portal for industry professionals who want to get involved in COVID-19 efforts?
CLARIFIED ANSWER: FDA recommends reaching out via email to connect with the appropriate contacts for industry professionals interested in getting involved.
VERBATIM QUESTION: Is there a portal for industry professionals who want to get involved in COVID-19 efforts?
VERBATIM ANSWER: It might be most expedient if you would shoot me an email and we can pick up the conversation from there. Sara, S-A-R-A.brenner, B as in Blue, R-E-N-N- E-R@fda.hhs.gov.
SPEAKER QUESTION: Jeff Kerriberry
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: industry involvement, COVID-19 response, FDA contacts
REVIEW FLAG: False


#### 7. Validity of Testing Methods on Deceased Patients

QA Block 7-1
CLARIFIED QUESTION: What is the applicability and validity of current COVID-19 tests, such as nasopharyngeal or serology tests, for use on deceased patients, given that none of the kits have cateveric indications for use?
CLARIFIED ANSWER: FDA acknowledges the question but has not specifically authorized COVID-19 tests for use on deceased patients. Labs using EUA-authorized devices may perform validations like bridging studies without needing FDA submission.
VERBATIM QUESTION: Hi. Yes thank you. My question deals with the applicability of the tests that are currently available whether they be nasopharyngeal or serology testing about their applicability and validity on deceased patients since none of those kits have cateveric indications for use at this point?
VERBATIM ANSWER: That is correct. That is a question I'm going to take back and get prepared for. And Alice if you were to shoot us an email to our cdrh-eua-templates address we will answer you directly. and on the next call after we've been able to provide some advice and guidance we will respond more globally with an answer to that. So it's a great question. I know we've authorized an Ebola test for such a situation but to my knowledge we have not specifically authorized that. If you're a lab that is using an EUA authorized device, you're and LDT lab you have the ability to validate that through some sort of bridging study or whatever validation that you think is worthy of that and no FDA submission is required for that particular application.
SPEAKER QUESTION: Alice Jones
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test validity on deceased patients, cateveric testing, EUA device lab validation
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What is the process for labs using an EUA-authorized device to validate an application for deceased patient testing without FDA submission?
CLARIFIED ANSWER: Labs using an EUA-authorized device for deceased patient testing can validate through a bridging study or equivalent validation without FDA submission.
VERBATIM QUESTION: What is the process for labs using an EUA-authorized device to validate an application for deceased patient testing without FDA submission?
VERBATIM ANSWER: If you're a lab that is using an EUA authorized device, you're and LDT lab you have the ability to validate that through some sort of bridging study or whatever validation that you think is worthy of that and no FDA submission is required for that particular application.
SPEAKER QUESTION: Alice Jones
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA device validation, deceased patient testing, FDA submission
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Can laboratories perform bridging studies or other validations on their own authority for specific applications outside the original authorization scope?
CLARIFIED ANSWER: Labs using EUA-authorized devices, particularly LDT labs, can independently perform bridging studies or validations for specific applications without FDA submission.
VERBATIM QUESTION: Can laboratories perform bridging studies or other validations on their own authority for specific applications outside the original authorization scope?
VERBATIM ANSWER: If you're a lab that is using an EUA authorized device, you're and LDT lab you have the ability to validate that through some sort of bridging study or whatever validation that you think is worthy of that and no FDA submission is required for that particular application.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: bridging studies, laboratory validations, EUA-authorized devices
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Has the FDA authorized any COVID-19 tests for deceased patient applications similar to the Ebola test authorization?
CLARIFIED ANSWER: The FDA has not specifically authorized any COVID-19 tests for deceased patient applications as was done for Ebola. Labs using EUA-authorized devices may validate such use through appropriate validation studies without FDA submission.
VERBATIM QUESTION: Has the FDA authorized any COVID-19 tests for deceased patient applications similar to the Ebola test authorization?
VERBATIM ANSWER: That is correct. That is a question I'm going to take back and get prepared for. And Alice if you were to shoot us an email to our cdrh-eua-templates address we will answer you directly. and on the next call after we've been able to provide some advice and guidance we will respond more globally with an answer to that. So it's a great question. I know we've authorized an Ebola test for such a situation but to my knowledge we have not specifically authorized that. If you're a lab that is using an EUA authorized device, you're and LDT lab you have the ability to validate that through some sort of bridging study or whatever validation that you think is worthy of that and no FDA submission is required for that particular application.
SPEAKER QUESTION: Alice Jones
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 tests for deceased patients, EUA device validation, Comparison to Ebola testing
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: If guidance is needed for using COVID-19 tests on deceased patients, where should developers or labs direct such questions?
CLARIFIED ANSWER: Developers or labs can email the FDA at cdrh-eua-templates for guidance on using COVID-19 tests on deceased patients. FDA will provide a direct response and address the topic broadly in a future meeting.
VERBATIM QUESTION: If guidance is needed for using COVID-19 tests on deceased patients, where should developers or labs direct such questions?
VERBATIM ANSWER: That is correct. That is a question I'm going to take back and get prepared for. And Alice if you were to shoot us an email to our cdrh-eua-templates address we will answer you directly. and on the next call after we've been able to provide some advice and guidance we will respond more globally with an answer to that.
SPEAKER QUESTION: Alice Jones
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 tests for deceased patients, FDA guidance, EUA process
REVIEW FLAG: False


#### 8. Clarifying EUA Pathway for Quantitative COVID-19 Assays

QA Block 8-1
CLARIFIED QUESTION: Does the EUA pathway under Policy D allow a serology test to be a quantitative test, or do we have to submit a 510(k) to make it a quantitative test?
CLARIFIED ANSWER: FDA may authorize a quantitative serology test under Policy D, but they need to verify if it falls under that pathway. Submitting an email to their address is encouraged to clarify the specific question.
VERBATIM QUESTION: Does the EUA pathway under Policy D allow a serology test to be a quantitative test, or do we have to submit a 510(k) to make it a quantitative test?
VERBATIM ANSWER: I think that is something that we can authorize if you want to submit something. That is - whether that's covered under that particular Pathway D I would want to double check for sure. So if you were to send an email to our cdrh-eua-templates address and ask that specific question I'd like to verify. And then once again once we've been able to address your specific question we can make that more broadly, that information more broadly available through one of our town hall meetings.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA pathway under Policy D, Quantitative serology test, 510(k) submission
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Is the FDA currently not reviewing quantitative tests?
CLARIFIED ANSWER: FDA may not currently review quantitative tests, but further clarification and involvement from Dr. Timothy Stenzel is suggested.
VERBATIM QUESTION: Is the FDA currently not reviewing quantitative tests?
VERBATIM ANSWER: Okay. Well ask them to contact - go back to that email address and asked them to bring me involved okay Timothy Stenzel. Ask them to involve me okay?
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA review of quantitative tests, process for EUA submission
REVIEW FLAG: True

QA Block 8-3
CLARIFIED QUESTION: Is it possible to obtain FDA authorization for a serology test measuring IgG and IgM quantitatively under Pathway D?
CLARIFIED ANSWER: FDA believes such authorization may be feasible, but confirmation on coverage under Pathway D requires further verification via email.
VERBATIM QUESTION: Is it possible to obtain FDA authorization for a serology test measuring IgG and IgM quantitatively under Pathway D?
VERBATIM ANSWER: I'm - I think that is something that we can authorize if you want to submit something. That is - whether that's covered under that particular Pathway D I would want to double check for sure. So if you were to send an email to our cdrh-eua-templates address and ask that specific question I'd like to verify.
SPEAKER QUESTION: Jackie Chin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, Pathway D, FDA EUA process
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What steps should a developer take to resolve discrepancies or miscommunications regarding the review process for quantitative tests?
CLARIFIED ANSWER: FDA advises sending an email to the specified address and requesting direct involvement from the FDA IVD Director to resolve discrepancies or miscommunications.
VERBATIM QUESTION: What steps should a developer take to resolve discrepancies or miscommunications regarding the review process for quantitative tests?
VERBATIM ANSWER: Well ask them to contact - go back to that email address and asked them to bring me involved okay Timothy Stenzel. Ask them to involve me okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: quantitative tests, FDA communication, discrepancies resolution
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Who should developers contact within the FDA if a submitted inquiry requires escalation or verification?
CLARIFIED ANSWER: Developers should email the CDRH-EUA-templates address and request that Dr. Tim Stenzel be involved for escalation or verification.
VERBATIM QUESTION: Who should developers contact within the FDA if a submitted inquiry requires escalation or verification?
VERBATIM ANSWER: Well ask them to contact - go back to that email address and asked them to bring me involved okay Timothy Stenzel. Ask them to involve me okay?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA inquiry escalation, Contact procedure
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: How does the FDA plan to share clarification about quantitative test authorization more broadly with concerned stakeholders?
CLARIFIED ANSWER: FDA will share clarification about quantitative test authorization more broadly through town hall meetings after addressing specific stakeholder questions.
VERBATIM QUESTION: How does the FDA plan to share clarification about quantitative test authorization more broadly with concerned stakeholders?
VERBATIM ANSWER: And then once again once we've been able to address your specific question we can make that more broadly, that information more broadly available through one of our town hall meetings.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: quantitative test authorization, stakeholder communication, town hall meetings
REVIEW FLAG: False


#### 9. Antibody Class Specificity Responsibility: Labs or Manufacturers?

QA Block 9-1
CLARIFIED QUESTION: Are laboratories that are validating commercially available tests expected to perform antibody class specificity studies for serological testing, or is that an expectation of the manufacturer?
CLARIFIED ANSWER: Antibody class specificity studies are part of FDA's guidance to manufacturers. Specific guidance for laboratories developing tests (LDTs) requires follow-up through direct inquiry.
VERBATIM QUESTION: Are laboratories that are validating commercially available tests expected to perform antibody class specificity studies for serological testing, or is that an expectation of the manufacturer?
VERBATIM ANSWER: Yes. That is part of our guidance to manufacturers. And I am not necessarily up to speed on what our guidance is to say an LDT. And I would want to give you a very direct and transparent and clear answer to that David. Could you send an email to our EUA address and ask for me to be involved in answering that question and we'll get back to you really, really quickly.
SPEAKER QUESTION: David Grenache
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antibody class specificity, serological test validation, FDA guidance
REVIEW FLAG: False


#### 10. Listing Diagnostic Test Kits on FDA FAQ Page

QA Block 10-1
CLARIFIED QUESTION: When a company notifies the FDA under Policy C of their intent to distribute a test while their EUA is being reviewed, should the company appear on the associated FAQ page?
CLARIFIED ANSWER: Yes, companies notifying the FDA under Policy C about their intent to distribute while their EUA is being reviewed should appear on the FAQ page. If not listed, they should contact the FDA through the EUA template to request listing.
VERBATIM QUESTION: When a company notifies the FDA under Policy C of their intent to distribute a test while their EUA is being reviewed, should the company appear on the associated FAQ page?
VERBATIM ANSWER: Yes, and we're listing those. So if we have not listed them yet please ping us at the EUA template and ask for them to be listed.
SPEAKER QUESTION: Nikki
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy C notifications, FAQ page listing, Diagnostic tests
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: If a molecular test is not listed on the FDA's FAQ page under Policy C, can developers contact the FDA via the EUA template to request listing?
CLARIFIED ANSWER: Yes, developers can contact the FDA via the EUA template to request listing if a molecular test is not listed on the FDA's FAQ page under Policy C.
VERBATIM QUESTION: If a molecular test is not listed on the FDA's FAQ page under Policy C, can developers contact the FDA via the EUA template to request listing?
VERBATIM ANSWER: Yes, and we're listing those. So if we have not listed them yet please ping us at the EUA template and ask for them to be listed.
SPEAKER QUESTION: Nikki
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Molecular tests, FDA FAQ listing, EUA template contact
REVIEW FLAG: False


#### 11. State Authority Over Home Use Serology Testing

QA Block 11-1
CLARIFIED QUESTION: Can states authorize home use serology tests that have not received an EUA?
CLARIFIED ANSWER: The FDA is not aware of states authorizing home use serology tests without an EUA, but states can authorize tests in collaboration with the FDA. Developers should contact the FDA, and decisions will involve state and FDA interaction.
VERBATIM QUESTION: Can states authorize home use serology tests that have not received an EUA?
VERBATIM ANSWER: It has not been to our knowledge something that the states are doing. And I was not aware that New York was doing that. We of course are working with states who are able to authorize tests and we will reach out to New York about that. But we would ask that developers of home use test that they reach out to the FDA. And then if there's something that a state may be willing to do we can interact with that state to make a decision.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home use serology tests, state authorization, FDA collaboration
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Is it allowed for a company to create test kits for home collection that are then shipped back to the company for testing?
CLARIFIED ANSWER: The FDA is not aware of states authorizing such practices or that New York is doing so. Developers of home-use tests should reach out to the FDA, and the FDA can work with the respective state to make a decision if needed.
VERBATIM QUESTION: Is it allowed for a company to create test kits for home collection that are then shipped back to the company for testing?
VERBATIM ANSWER: So that is also a great question. It has not been to our knowledge something that the states are doing. And I was not aware that New York was doing that. We of course are working with states who are able to authorize tests and we will reach out to New York about that. But we would ask that developers of home use test that they reach out to the FDA. And then if there's something that a state may be willing to do we can interact with that state to make a decision.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home-use test kits, state authorization, FDA oversight
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: What steps does the FDA expect developers of home use serology tests to take before reaching out to states?
CLARIFIED ANSWER: The FDA asks developers of home use serology tests to reach out to the FDA first, and if needed, the FDA can then coordinate with states to make a decision.
VERBATIM QUESTION: What steps does the FDA expect developers of home use serology tests to take before reaching out to states?
VERBATIM ANSWER: But we would ask that developers of home use test that they reach out to the FDA. And then if there's something that a state may be willing to do we can interact with that state to make a decision.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home use serology tests, FDA coordination with states, developer responsibilities
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: What is the FDA's process when a state expresses interest in authorizing a diagnostic test that involves home collection?
CLARIFIED ANSWER: The FDA works with states interested in authorizing home use diagnostic tests. Developers are encouraged to contact the FDA, and the FDA can coordinate with states to assist them in making decisions on such tests.
VERBATIM QUESTION: What is the FDA's process when a state expresses interest in authorizing a diagnostic test that involves home collection?
VERBATIM ANSWER: So that is also a great question. It has not been to our knowledge something that the states are doing. And I was not aware that New York was doing that. We of course are working with states who are able to authorize tests and we will reach out to New York about that. But we would ask that developers of home use test that they reach out to the FDA. And then if there's something that a state may be willing to do we can interact with that state to make a decision.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: state authorization for home tests, FDA coordination for authorization
REVIEW FLAG: False


#### 12. Clarifying Serology Test Complexity and Approval Processes

QA Block 12-1
CLARIFIED QUESTION: Will there be any type of notification to alert doctors' offices that serology test kits are not being used in the proper settings?
CLARIFIED ANSWER: The FDA has already pointed out some notifications and will check into making the information more public, as it is already available on their FAQ page.
VERBATIM QUESTION: Will there be any type of notification to alert doctors' offices that serology test kits are not being used in the proper settings?
VERBATIM ANSWER: Okay, we've point out some notifications already. I am not aware that we have said that they are currently high complexity. And so I will check into that and if we can we'll make that more public. It is on our FAQ page though already.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test notifications, proper test usage, FAQ page clarification
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Is it possible for third-party approvals or reviews to be used for submissions of serology tests?
CLARIFIED ANSWER: FDA stated they are unsure whether third-party reviews are being used for EUA submissions and plan to investigate the matter further.
VERBATIM QUESTION: Is it possible for third-party approvals or reviews to be used for submissions of serology tests?
VERBATIM ANSWER: Wow that is a fantastic question. That's the first time I've gotten that question. I do not know if we're using third parties for EUA. We - I will address that. I will look into that question on my next quick address which I have about three or four of a week now.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Third-party review, EUA submissions, Serology tests
REVIEW FLAG: True

QA Block 12-4
CLARIFIED QUESTION: Are there plans to update the FDA website to make information about test complexity clearer?
CLARIFIED ANSWER: The FDA will work to address and resolve confusion about test complexity on their website.
VERBATIM QUESTION: Are there plans to update the FDA website to make information about test complexity clearer?
VERBATIM ANSWER: I agree. We'll try to resolve the confusion on that Web site.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA website updates, test complexity, serology tests
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What steps should developers take if they encounter contradictory guidance on FDA resources?
CLARIFIED ANSWER: The FDA agrees to resolve contradictory guidance on their website to address confusion.
VERBATIM QUESTION: What steps should developers take if they encounter contradictory guidance on FDA resources?
VERBATIM ANSWER: I agree. We'll try to resolve the confusion on that Web site.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA website guidance, resolving contradictions
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Can developers reach out to the FDA through email to address confusion regarding test complexity designations?
CLARIFIED ANSWER: Developers can reach out to the FDA through email to address specific questions and resolve any confusion.
VERBATIM QUESTION: Can developers reach out to the FDA through email to address confusion regarding test complexity designations?
VERBATIM ANSWER: Well alternatively you can also go to the email address and ask that specifically you get that specifically address but that's a great question.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test complexity clarification, FDA email communication
REVIEW FLAG: False


#### 13. FDA Recommendations on Phosphate Buffered Saline vs. Normal Saline

QA Block 13-1
CLARIFIED QUESTION: Do you have data or bridging studies to show the superiority of phosphate buffered saline (PBS) over normal saline?
CLARIFIED ANSWER: FDA stated that they provided vendors with PBS or equivalents. While normal saline is acceptable, FDA considers buffered saline preferable but not mandatory.
VERBATIM QUESTION: Do you have data or bridging studies to show the superiority of phosphate buffered saline (PBS) over normal saline?
VERBATIM ANSWER: I think we provided a couple vendors with a PBS and/or an equivalent if I'm correct. Normal saline will work it's just that our thoughts are that if a buffered saline could be used that that is probably preferable but normal saline is still allowed.
SPEAKER QUESTION: Abby
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: PBS vs. normal saline, buffered saline recommendations, saline testing standards
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Do you have a specific formulation of phosphate buffered saline (PBS) that you're recommending?
CLARIFIED ANSWER: The FDA has provided a couple of vendor options for PBS or equivalents. While normal saline is acceptable, the FDA believes buffered saline is preferable but not required.
VERBATIM QUESTION: Do you have a specific formulation of phosphate buffered saline (PBS) that you're recommending?
VERBATIM ANSWER: I think we provided a couple vendors with a PBS and/or an equivalent if I'm correct. Normal saline will work it's just that our thoughts are that if a buffered saline could be used that that is probably preferable but normal saline is still allowed.
SPEAKER QUESTION: Abby
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: phosphate buffered saline (PBS), FDA recommendations, diagnostic testing materials
REVIEW FLAG: False


#### 14. EUA Filing Requirements for Subsidiaries with Different Manufacturers

QA Block 14-1
CLARIFIED QUESTION: If two subsidiaries of the same parent company want to market the same or similar COVID-19 test, do both need to file an EUA followed by a 510K, or does only one need to file?
CLARIFIED ANSWER: The specific answer isn't certain; however, if the design is the same but manufactured in different locations, it could relate to a legal manufacturer question. It might require two EUAs, with one entity referencing the other's data in its submission, but this should be confirmed with FDA staff.
VERBATIM QUESTION: If two subsidiaries of the same parent company want to market the same or similar COVID-19 test, do both need to file an EUA followed by a 510K, or does only one need to file?
VERBATIM ANSWER: You know, I don't know the best answer to that. I mean I would think that there would be easy routes to go through if it's the same design manufactured in separate places. It actually may just be a paper question of who's the legal manufacturer. If it needs to be two different EUA's the one entity can refer to the data in the first entity's package and basically submit a shell is what I'm thinking. But I would want to confirm all of that with our staff.
SPEAKER QUESTION: Margot Enright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA filing requirements, subsidiary COVID-19 test approvals, FDA filing clarifications
REVIEW FLAG: True

QA Block 14-2
CLARIFIED QUESTION: If one of the tests is manufactured in the US and the other outside the US with different manufacturing sites and raw material sources, does this make it a different product for EUA filing purposes?
CLARIFIED ANSWER: FDA suggests that if tests have the same design but are manufactured in separate locations, it may depend on who the legal manufacturer is. If separate EUAs are needed, data from one entity can be referenced in a 'shell' application, but confirmation with FDA staff is recommended.
VERBATIM QUESTION: If one of the tests is manufactured in the US and the other outside the US with different manufacturing sites and raw material sources, does this make it a different product for EUA filing purposes?
VERBATIM ANSWER: I mean I would think that there would be easy routes to go through if it's the same design manufactured in separate places. It actually may just be a paper question of who's the legal manufacturer. If it needs to be two different EUA's the one entity can refer to the data in the first entity's package and basically submit a shell is what I'm thinking. But I would want to confirm all of that with our staff.
SPEAKER QUESTION: Margot Enright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA filings, manufacturing site differences
REVIEW FLAG: True

QA Block 14-3
CLARIFIED QUESTION: Do the rules that allow only one 510K for the same product apply to EUA filings if the manufacturing sites and raw material sources are different?
CLARIFIED ANSWER: The FDA does not have a definitive answer but suggests that if the products share the same design but are manufactured in different locations, it might depend on legal manufacturer designation. If two EUAs are required, one could reference the data from the other. Confirmation with FDA staff is necessary.
VERBATIM QUESTION: Do the rules that allow only one 510K for the same product apply to EUA filings if the manufacturing sites and raw material sources are different?
VERBATIM ANSWER: You know, I don't know the best answer to that. I mean I would think that there would be easy routes to go through if it's the same design manufactured in separate places. It actually may just be a paper question of who's the legal manufacturer. If it needs to be two different EUA's the one entity can refer to the data in the first entity's package and basically submit a shell is what I'm thinking. But I would want to confirm all of that with our staff.
SPEAKER QUESTION: Margot Enright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA filings, 510K rules, Manufacturing sites
REVIEW FLAG: True

QA Block 14-4
CLARIFIED QUESTION: What is the FDA's protocol for listing two separate manufacturers in an EUA submission?
CLARIFIED ANSWER: FDA recommends contacting the templates email address for clarification on listing two manufacturers in an EUA submission, but does not foresee issues with seeking authorization.
VERBATIM QUESTION: What is the FDA's protocol for listing two separate manufacturers in an EUA submission?
VERBATIM ANSWER: I'm not aware of listing two manufacturers. That's best addressed to our templates email address to be certain. I don't see necessarily issues. We would again, you're going to seek EUA authorization for these?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, multiple manufacturers, FDA clarification
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: Can an entity reference another entity's data package to file a separate or 'shell' EUA?
CLARIFIED ANSWER: If two EUAs are needed, one entity may reference the data from the first entity's package and submit a shell, but FDA recommends confirming this with their staff.
VERBATIM QUESTION: Can an entity reference another entity's data package to file a separate or 'shell' EUA?
VERBATIM ANSWER: If it needs to be two different EUA's the one entity can refer to the data in the first entity's package and basically submit a shell is what I'm thinking. But I would want to confirm all of that with our staff.
SPEAKER QUESTION: Margot Enright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA data referencing, Shell EUA submission
REVIEW FLAG: True

QA Block 14-6
CLARIFIED QUESTION: How is the legal manufacturer determined when the same test is produced at separate manufacturing sites?
CLARIFIED ANSWER: The legal manufacturer may depend on whether the design is the same, even if manufacturing occurs in separate locations; this might involve filing EUAs with reference to the original data. Confirmation with FDA staff is recommended.
VERBATIM QUESTION: How is the legal manufacturer determined when the same test is produced at separate manufacturing sites?
VERBATIM ANSWER: You know, I don't know the best answer to that. I mean I would think that there would be easy routes to go through if it's the same design manufactured in separate places. It actually may just be a paper question of who's the legal manufacturer. If it needs to be two different EUA's the one entity can refer to the data in the first entity's package and basically submit a shell is what I'm thinking. But I would want to confirm all of that with our staff.
SPEAKER QUESTION: Margot Enright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: legal manufacturer, EUA submissions, manufacturing sites
REVIEW FLAG: True


#### 15. CLIA Certification and Serology Testing Requirements Discussed

QA Block 15-1
CLARIFIED QUESTION: If a test kit is under the notification arm, can it only be used in laboratories?
CLARIFIED ANSWER: Test kits under the notification arm require at least a CLIA waiver certificate to be used, even in a waived environment. Laboratories must comply with CMS regulations.
VERBATIM QUESTION: If a test kit is under the notification arm, can it only be used in laboratories?
VERBATIM ANSWER: It's my understanding the CMS requires a certificate no matter where the testing is performed even if it is a CLIA waived test there must be a certificate of CLIA waiver in order for the test to be performed even a CLIA waived designated test to be performed in that setting. And so that is coming, that's our understanding what CMS opinion is on this.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Notification arm test kits, CLIA certification
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Can a physician perform, interpret, and use the test for the patient without being associated with a laboratory certified as moderate or high complexity?
CLARIFIED ANSWER: According to FDA, tests under EUA for serology are only authorized for moderate or high complexity environments, not CLIA-waived settings. CMS also requires certification wherever testing occurs, including CLIA-waived environments.
VERBATIM QUESTION: Can a physician perform, interpret, and use the test for the patient without being associated with a laboratory certified as moderate or high complexity?
VERBATIM ANSWER: Okay, well regarding the single EUA authorization for serology that we've granted that was designated by us as suitable for a moderate or high complexity environment but not a CLIA waived environment so we did not deem it as waived. It's my understanding the CMS requires a certificate no matter where the testing is performed even if it is a CLIA waived test there must be a certificate of CLIA waiver in order for the test to be performed even a CLIA waived designated test to be performed in that setting. And so that is coming, that's our understanding what CMS opinion is on this. I would refer any questions to them though on this.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA serology authorizations, CLIA certification requirements
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Is it true that capillary blood finger sticks are not allowed?
CLARIFIED ANSWER: Capillary blood finger sticks can be used if the tests are validated in high complexity environments or approved for CLIA waived environments.
VERBATIM QUESTION: Is it true that capillary blood finger sticks are not allowed?
VERBATIM ANSWER: As far as the use of capillary is concerned capillary or finger stick blood as long as tests are validated and for capillary they could be used even in a high complexity type environment. A high complexity lab could set up a finger stick station to be able to do these tests under their high complexity certificate. Again these test should be validated for capillary. If a developer wants to have a point-of-care test for serology or another test - well it would be serology here. We utilize a finger stick. That's an acceptable sample type as long as it's been validated and then be used in that CLIA waived environment and we authorize it, we review the data and we are able presumably we're able to deem it as a CLIA waived test.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: capillary blood finger sticks, test validation, CLIA certification
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: Is it stated explicitly anywhere, such as in bold type, that finger sticks cannot be used?
CLARIFIED ANSWER: Finger sticks can be used if validated, even in high complexity labs, but there is no mention of it being explicitly stated in bold type that they are not allowed.
VERBATIM QUESTION: Is it stated explicitly anywhere, such as in bold type, that finger sticks cannot be used?
VERBATIM ANSWER: As far as the use of capillary is concerned capillary or finger stick blood as long as tests are validated and for capillary they could be used even in a high complexity type environment. A high complexity lab could set up a finger stick station to be able to do these tests under their high complexity certificate. Again these test should be validated for capillary.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: finger stick use, validation requirements, high complexity labs
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: What is the significance of the CMS requirement for a CLIA waiver certificate, even for tests deemed CLIA waived, and how does it impact test deployment?
CLARIFIED ANSWER: The CMS requires a CLIA certificate for all testing sites, even for CLIA-waived tests, ensuring proper authorization for test performance. For specific details, CMS should be contacted.
VERBATIM QUESTION: What is the significance of the CMS requirement for a CLIA waiver certificate, even for tests deemed CLIA waived, and how does it impact test deployment?
VERBATIM ANSWER: It's my understanding the CMS requires a certificate no matter where the testing is performed even if it is a CLIA waived test there must be a certificate of CLIA waiver in order for the test to be performed even a CLIA waived designated test to be performed in that setting. And so that is coming, that's our understanding what CMS opinion is on this. I would refer any questions to them though on this.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CMS requirements, CLIA waiver, test deployment
REVIEW FLAG: False

QA Block 15-6
CLARIFIED QUESTION: Can capillary or finger-stick blood samples be used for serology tests in high-complexity laboratories, and what specific validations are required?
CLARIFIED ANSWER: Capillary or finger-stick blood samples can be used for serology tests in high-complexity laboratories if they are properly validated. High-complexity labs can set up finger-stick stations to conduct these tests.
VERBATIM QUESTION: Can capillary or finger-stick blood samples be used for serology tests in high-complexity laboratories, and what specific validations are required?
VERBATIM ANSWER: As far as the use of capillary is concerned capillary or finger stick blood as long as tests are validated and for capillary they could be used even in a high complexity type environment. A high complexity lab could set up a finger stick station to be able to do these tests under their high complexity certificate. Again these test should be validated for capillary.
SPEAKER QUESTION: Brandt Mitler
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: capillary blood samples, finger-stick validation, high-complexity labs
REVIEW FLAG: False

QA Block 15-7
CLARIFIED QUESTION: Under what circumstances would the FDA deem a point-of-care serology test using finger-stick blood suitable for a CLIA-waived environment?
CLARIFIED ANSWER: FDA requires a finger-stick test for point-of-care serology to be validated. If the data is reviewed and authorized by FDA, it may be deemed CLIA-waived.
VERBATIM QUESTION: Under what circumstances would the FDA deem a point-of-care serology test using finger-stick blood suitable for a CLIA-waived environment?
VERBATIM ANSWER: If a developer wants to have a point-of-care test for serology or another test - well it would be serology here. We utilize a finger stick. That's an acceptable sample type as long as it's been validated and then be used in that CLIA waived environment and we authorize it, we review the data and we are able presumably we're able to deem it as a CLIA waived test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of finger-stick tests, Point-of-care serology, CLIA-waived classification
REVIEW FLAG: False


#### 16. FDA Guidance on Importing Unregistered UTM for Authorization

QA Block 16-1
CLARIFIED QUESTION: What is the FDA's stance on bringing in UTM from a foreign manufacturer that may not be listed or registered?
CLARIFIED ANSWER: The FDA recommends sending details about the foreign UTM manufacturer to the EUA templates address so they can route it to the team working on alternate sources and importation for further evaluation.
VERBATIM QUESTION: What is the FDA's stance on bringing in UTM from a foreign manufacturer that may not be listed or registered?
VERBATIM ANSWER: That is a great question. If you have a vendor in mind and you want to have us make this determination if you send in that to our EUA templates address we will route that to the team that is working on alternate ETM sources. And also they aid in importation of such and they can address this question specifically.
SPEAKER QUESTION: Kevin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: foreign UTM importation, EUA process, FDA evaluation
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Is there any kind of fast track process to get unauthorized UTM from a foreign manufacturer approved for use?
CLARIFIED ANSWER: FDA advises submitting details of the vendor to the EUA templates address for review. The submission will be routed to the team working on alternative ETM sources and importation, who can address this request specifically.
VERBATIM QUESTION: Is there any kind of fast track process to get unauthorized UTM from a foreign manufacturer approved for use?
VERBATIM ANSWER: That is a great question. If you have a vendor in mind and you want to have us make this determination if you send in that to our EUA templates address we will route that to the team that is working on alternate ETM sources. And also they aid in importation of such and they can address this question specifically.
SPEAKER QUESTION: Kevin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: UTM importation, fast track process, FDA EUA submission
REVIEW FLAG: False


#### 17. Expanding Serology Testing with Telehealth and Home-Based Solutions

QA Block 17-1
CLARIFIED QUESTION: If we use serology tests at an appropriate site, will we be able to use telehealth for the physician consultation?
CLARIFIED ANSWER: FDA allows telehealth in situations where serology tests fall within CLIA-waived settings with proper healthcare staffing. For home-based serology tests, EUA authorization is required, with considerations for usability, result interpretation, and patient safety. FDA is open to telehealth, including video links, to aid in test use and result interpretation.
VERBATIM QUESTION: If we use serology tests at an appropriate site, will we be able to use telehealth for the physician consultation?
VERBATIM ANSWER: As far as telehealth or alternate sites or home use if something is within - is deemed as CLIA waived because it has been authorized by the FDA and it can be used therefore in a CLIA waived setting it that setting is going to be staffed by health care folks who are able to perform that testing. Usually telehealth would be used in more of the home situation and those as we stated before require EUA authorization for a home-based test. We are very open to a home-based serology test. The important factors are, you know, how easy for this a patient, untrained patient to perform the testing? How easy is it to them to read the test results and how easy is it for them to interpret those results? Now for a typical rapid serology test there's questions in each of those places and also we do look at safety. But we are very open to telehealth especially with a video link to assist patients in performing a serology test at home, reading the results of the serology test and then also interpreting the results for what it means.
SPEAKER QUESTION: Ethan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Telehealth for serology tests, CLIA-waived settings, Home-based diagnostic testing
REVIEW FLAG: False

QA Block 17-2
CLARIFIED QUESTION: Can serology tests not authorized under EUA be used for diagnosis?
CLARIFIED ANSWER: The FDA has not authorized serology tests, including those not under EUA, to be used as the sole basis for diagnosis due to scientific challenges such as antibodies developing later or persisting after infection clearance.
VERBATIM QUESTION: Can serology tests not authorized under EUA be used for diagnosis?
VERBATIM ANSWER: We have not yet authorize the serology test as a sole basis of diagnosis. There are scientific challenges with that although if a developer wants to pursue that we will certainly engage in conversation. But obviously before antibodies are developed to SARS CV-2 the patient can be infected and that also antibody tend - antibodies tend to persist for long after an infection. And so they can be antibody positive but be completely cleared of the virus.
SPEAKER QUESTION: Ethan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test authorization, Diagnostic limitations, Scientific challenges
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: What are the requirements for a telehealth-based home serology test to be authorized by the FDA?
CLARIFIED ANSWER: The FDA is open to authorizing telehealth-based home serology tests if they are easy for untrained patients to perform, read, and interpret, and if safety concerns are addressed. A video link can assist with testing and interpretation.
VERBATIM QUESTION: What are the requirements for a telehealth-based home serology test to be authorized by the FDA?
VERBATIM ANSWER: We are very open to a home-based serology test. The important factors are, you know, how easy for this a patient, untrained patient to perform the testing? How easy is it to them to read the test results and how easy is it for them to interpret those results? Now for a typical rapid serology test there's questions in each of those places and also we do look at safety. But we are very open to telehealth especially with a video link to assist patients in performing a serology test at home, reading the results of the serology test and then also interpreting the results for what it means.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Telehealth in diagnostics, Home serology test requirements, FDA authorization criteria
REVIEW FLAG: False

QA Block 17-4
CLARIFIED QUESTION: What are the scientific challenges preventing serology tests from being authorized as the sole basis for diagnosis?
CLARIFIED ANSWER: FDA has not authorized serology tests as the sole basis for diagnosis due to scientific concerns. Antibodies develop after infection begins, and they can remain detectable long after the virus is cleared, making them unreliable for definitive diagnosis.
VERBATIM QUESTION: What are the scientific challenges preventing serology tests from being authorized as the sole basis for diagnosis?
VERBATIM ANSWER: So we have not yet authorize the serology test as a sole basis of diagnosis. There are scientific challenges with that although if a developer wants to pursue that we will certainly engage in conversation. But obviously before antibodies are developed to SARS CV-2 the patient can be infected and that also antibody tend - antibodies tend to persist for long after an infection. And so they can be antibody positive but be completely cleared of the virus.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test limitations, diagnostic challenges
REVIEW FLAG: False

QA Block 17-5
CLARIFIED QUESTION: Can the FDA provide details on what would be required to pursue authorization of a serology test for sole diagnostic use?
CLARIFIED ANSWER: The FDA has not authorized serology tests for sole use in diagnosis due to scientific challenges, such as the timing of antibody development and persistence post-infection. Developers seeking authorization can engage with the FDA.
VERBATIM QUESTION: Can the FDA provide details on what would be required to pursue authorization of a serology test for sole diagnostic use?
VERBATIM ANSWER: We have not yet authorize the serology test as a sole basis of diagnosis. There are scientific challenges with that although if a developer wants to pursue that we will certainly engage in conversation. But obviously before antibodies are developed to SARS CV-2 the patient can be infected and that also antibody tend - antibodies tend to persist for long after an infection. And so they can be antibody positive but be completely cleared of the virus.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Sole diagnostic use, FDA authorization
REVIEW FLAG: False

QA Block 17-7
CLARIFIED QUESTION: What factors does the FDA consider when evaluating the safety of home-based serology tests?
CLARIFIED ANSWER: The FDA considers the ease for an untrained patient to perform the test, read the results, and interpret them, along with general safety, when evaluating home-based serology tests.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We are very open to a home-based serology test. The important factors are, you know, how easy for this a patient, untrained patient to perform the testing? How easy is it to them to read the test results and how easy is it for them to interpret those results? Now for a typical rapid serology test there's questions in each of those places and also we do look at safety.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home-based serology tests, FDA evaluation criteria, Safety considerations
REVIEW FLAG: False

QA Block 17-8
CLARIFIED QUESTION: Is a video link considered sufficient support for patients conducting serology tests at home?
CLARIFIED ANSWER: The FDA is open to using telehealth, including video links, to help patients perform, read, and interpret serology tests at home.
VERBATIM QUESTION: Is a video link considered sufficient support for patients conducting serology tests at home?
VERBATIM ANSWER: We are very open to telehealth especially with a video link to assist patients in performing a serology test at home, reading the results of the serology test and then also interpreting the results for what it means.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: telehealth for serology tests, home serology testing, use of video links
REVIEW FLAG: False


#### 18. Developing Plasma Panels for Serology Testing Collaboration

QA Block 18-1
CLARIFIED QUESTION: Is the panel of positive and negative plasma something that serology assay developers will have access to, or is it just for FDA to test submitted kits?
CLARIFIED ANSWER: The FDA, as part of an interagency collaboration, is prioritizing collecting samples to test at a central lab. They hope to later develop panels for serology assay developers if enough plasma remains, and will announce availability publicly if achieved.
VERBATIM QUESTION: Is the panel of positive and negative plasma something that serology assay developers will have access to, or is it just for FDA to test submitted kits?
VERBATIM ANSWER: So this is an interagency program involving multiple agencies. We are collaborating on this. The first priority is to be able to collect enough of these samples to be able to test at a central lab various tests that can be sent to this facility. If you're willing to participate you can email us at their EUA templates address and volunteer to be a part of that. We are hoping that there will be enough remaining plasma and/or sera to develop panels that we could send to developers. So at this point it's probably best to stay tuned. If there is such panels that can be shipped to developers we will make that publicly known.
SPEAKER QUESTION: Mehti
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology assay panels, developer access, FDA plasma testing
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: What is the procedure for volunteering to participate in the central lab testing program?
CLARIFIED ANSWER: To volunteer, email the FDA at their EUA templates address and express your interest in participating.
VERBATIM QUESTION: What is the procedure for volunteering to participate in the central lab testing program?
VERBATIM ANSWER: If you're willing to participate you can email us at their EUA templates address and volunteer to be a part of that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: volunteering process, central lab testing, EUA templates
REVIEW FLAG: False

QA Block 18-3
CLARIFIED QUESTION: How can developers ensure they will be informed if panels become available for shipment?
CLARIFIED ANSWER: Developers can email the FDA at the EUA templates address to participate and stay informed. The FDA will publicly announce if panels for shipment become available.
VERBATIM QUESTION: How can developers ensure they will be informed if panels become available for shipment?
VERBATIM ANSWER: If you're willing to participate you can email us at their EUA templates address and volunteer to be a part of that. We are hoping that there will be enough remaining plasma and/or sera to develop panels that we could send to developers. So at this point it's probably best to stay tuned. If there is such panels that can be shipped to developers we will make that publicly known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Developer participation, Panel availability for developers, Communication process
REVIEW FLAG: False

QA Block 18-4
CLARIFIED QUESTION: What agencies are involved in the interagency program collaboration?
CLARIFIED ANSWER: The program is an interagency collaboration involving multiple agencies to collect samples and test at a central lab.
VERBATIM QUESTION: What agencies are involved in the interagency program collaboration?
VERBATIM ANSWER: So this is an interagency program involving multiple agencies. We are collaborating on this. The first priority is to be able to collect enough of these samples to be able to test at a central lab various tests that can be sent to this facility.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: interagency collaboration, sample collection, central laboratory testing
REVIEW FLAG: False

QA Block 18-5
CLARIFIED QUESTION: Will the remaining plasma/sera be prioritized for specific types of serology assay development?
CLARIFIED ANSWER: FDA hopes to have enough remaining plasma or sera to create panels for developers. If panels become available, FDA will announce it publicly.
VERBATIM QUESTION: Will the remaining plasma/sera be prioritized for specific types of serology assay development?
VERBATIM ANSWER: We are hoping that there will be enough remaining plasma and/or sera to develop panels that we could send to developers. So at this point it's probably best to stay tuned. If there is such panels that can be shipped to developers we will make that publicly known.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: plasma/sera distribution, serology assay development
REVIEW FLAG: False

QA Block 18-6
CLARIFIED QUESTION: Are there any criteria to qualify for participation in the interagency program?
CLARIFIED ANSWER: Interested participants can volunteer by emailing the FDA at their EUA templates address.
VERBATIM QUESTION: Are there any criteria to qualify for participation in the interagency program?
VERBATIM ANSWER: If you're willing to participate you can email us at their EUA templates address and volunteer to be a part of that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: interagency program, participation criteria, EUA process
REVIEW FLAG: False


#### 19. Handling Unauthorized Serology Tests and Patient Results

QA Block 19-1
CLARIFIED QUESTION: What should we do if companies sold serology test kits in Puerto Rico before notifying the FDA, and clinical labs issued reports based on these tests?
CLARIFIED ANSWER: FDA recommends sending an email to cdrh-eua-template@fda.hhs.gov for assistance regarding the issue, and they will work with individuals to resolve it.
VERBATIM QUESTION: What should we do if companies sold serology test kits in Puerto Rico before notifying the FDA, and clinical labs issued reports based on these tests?
VERBATIM ANSWER: Yes, that's an off-line question I think. So if you send an email to cdrh- eua-template at fda.hhs.gov with that question and ask that, I or Sara be involved will work with you to resolve that issue okay?
SPEAKER QUESTION: Marcos Lopez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test notification, FDA reporting requirements, Puerto Rico diagnostics
REVIEW FLAG: False

QA Block 19-2
CLARIFIED QUESTION: Should we inform patients that their reports may be invalid if serology tests were commercialized before FDA notification?
CLARIFIED ANSWER: FDA indicated that this issue should be addressed offline by contacting them via email to resolve it.
VERBATIM QUESTION: Should we inform patients that their reports may be invalid if serology tests were commercialized before FDA notification?
VERBATIM ANSWER: Yes, that's an off-line question I think. So if you send an email to cdrh-eua-template at fda.hhs.gov with that question and ask that, I or Sara be involved will work with you to resolve that issue okay?
SPEAKER QUESTION: Marcos Lopez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: invalid COVID-19 test results, FDA notification, follow-up process
REVIEW FLAG: False

QA Block 19-3
CLARIFIED QUESTION: Can the exact date that each company was allowed to commercialize their serology tests be published on a website?
CLARIFIED ANSWER: The FDA recommends emailing cdrh-eua-template@fda.hhs.gov to address this specific question about company's commercialization dates for serology tests.
VERBATIM QUESTION: Can the exact date that each company was allowed to commercialize their serology tests be published on a website?
VERBATIM ANSWER: Yes, that's an off-line question I think. So if you send an email to cdrh- eua-template at fda.hhs.gov with that question and ask that, I or Sara be involved will work with you to resolve that issue okay?
SPEAKER QUESTION: Marcos Lopez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test commercialization, FDA notification, Puerto Rico
REVIEW FLAG: False

QA Block 19-4
CLARIFIED QUESTION: Should we take action if serology test kits were sold before notification but the issue lies with the distributors, not the manufacturers?
CLARIFIED ANSWER: FDA advises submitting details via email to resolve questions about serology kits sold before notification, especially to clarify responsibilities of distributors versus manufacturers.
VERBATIM QUESTION: Should we take action if serology test kits were sold before notification but the issue lies with the distributors, not the manufacturers?
VERBATIM ANSWER: Yes, that's an off-line question I think. So if you send an email to cdrh- eua-template at fda.hhs.gov with that question and ask that, I or Sara be involved will work with you to resolve that issue okay?
SPEAKER QUESTION: Marcos Lopez
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology test kit notification, Off-label sales, FDA clarification process
REVIEW FLAG: False


#### 20. Guidance on EUA Waivers and Serology Test Resources

QA Block 20-1
CLARIFIED QUESTION: What does the waiver of GNP requirements under an EUA mean?
CLARIFIED ANSWER: Under an EUA, waivers of GNP requirements may apply, but essential elements like complaint handling and adverse event reporting must still be maintained. Details on waived provisions can be found on the FDA Authorization Page.
VERBATIM QUESTION: What does the waiver of GNP requirements under an EUA mean?
VERBATIM ANSWER: Yes, so under an EUA to waive any of the GNP requirements. One important element that must be retained is that you have a complaint handling system and adverse reporting, adverse event reporting so that your monitoring the performance of your tests on the market and if there are issues and you're required to report from the FDA that you do report in a timely way to the FDA. If you look at any of the decision statements on our FDA Authorization Page you will see what provisions are waived. I don't have them off the top of my head but if you look at those you will see what provision of GNP and CFRs are waived in an emergency situation. And if that doesn't address your question well enough you can come back to our EUA templates address and we'll answer any further questions.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA waivers, GNP requirements, FDA reporting obligations
REVIEW FLAG: False

QA Block 20-2
CLARIFIED QUESTION: Will further guidance be issued regarding GNP requirement waivers under an EUA?
CLARIFIED ANSWER: Under an EUA, some GNP requirements may be waived, but a complaint handling system and adverse reporting mechanisms must be retained. Details about waived provisions are available on the FDA Authorization Page. Further clarification can be sought through the EUA templates address.
VERBATIM QUESTION: Will further guidance be issued regarding GNP requirement waivers under an EUA?
VERBATIM ANSWER: Yes, so under an EUA to waive any of the GNP requirements. One important element that must be retained is that you have a complaint handling system and adverse reporting, adverse event reporting so that your monitoring the performance of your tests on the market and if there are issues and you're required to report from the FDA that you do report in a timely way to the FDA. If you look at any of the decision statements on our FDA Authorization Page you will see what provisions are waived. I don't have them off the top of my head but if you look at those you will see what provision of GNP and CFRs are waived in an emergency situation. And if that doesn't address your question well enough you can come back to our EUA templates address and we'll answer any further questions.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: GNP waivers, EUA guidelines, Regulatory compliance
REVIEW FLAG: False

QA Block 20-3
CLARIFIED QUESTION: Do you have sources for bulk COVID-19 protein antigen for the serology test?
CLARIFIED ANSWER: The FDA is trying to obtain bulk COVID-19 protein antigens for internal interagency work, but there are no current plans for distribution as these materials are usually proprietary. At least one public announcement mentions an entity willing to share serology tests, and interested parties should consult those announcements.
VERBATIM QUESTION: Do you have sources for bulk COVID-19 protein antigen for the serology test?
VERBATIM ANSWER: So I know that we are trying to obtain some of those for our own internal interagency work but at this time we don't have plans to distribute that. Those are usually proprietary. I know that there is at least one entity out there that is publicly announced that they are willing to transfer their serology tests to others so you can certainly look at those public announcements and reach out to them.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: bulk COVID-19 protein antigen, serology tests, material sourcing
REVIEW FLAG: False

QA Block 20-4
CLARIFIED QUESTION: Are government agencies pursuing efforts for bulk COVID-19 protein antigen in partnership with private entities?
CLARIFIED ANSWER: The FDA is trying to obtain bulk COVID-19 protein antigens for internal interagency work but has no plans to distribute them. These antigens are proprietary, and at least one entity has publicly offered their serology tests for transfer.
VERBATIM QUESTION: Are government agencies pursuing efforts for bulk COVID-19 protein antigen in partnership with private entities?
VERBATIM ANSWER: So I know that we are trying to obtain some of those for our own internal interagency work but at this time we don't have plans to distribute that. Those are usually proprietary. I know that there is at least one entity out there that is publicly announced that they are willing to transfer their serology tests to others so you can certainly look at those public announcements and reach out to them.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 protein antigen, government-private partnership, serology tests
REVIEW FLAG: False

QA Block 20-5
CLARIFIED QUESTION: What specific complaint handling and adverse event reporting requirements must be retained if GNP requirements are waived under an EUA?
CLARIFIED ANSWER: Under an EUA, even if GNP requirements are waived, maintaining a complaint handling system and adverse event reporting is mandatory to monitor product performance and report any issues promptly to the FDA.
VERBATIM QUESTION: What specific complaint handling and adverse event reporting requirements must be retained if GNP requirements are waived under an EUA?
VERBATIM ANSWER: Yes, so under an EUA to waive any of the GNP requirements. One important element that must be retained is that you have a complaint handling system and adverse reporting, adverse event reporting so that your monitoring the performance of your tests on the market and if there are issues and you're required to report from the FDA that you do report in a timely way to the FDA.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, adverse event reporting, complaint handling
REVIEW FLAG: False

QA Block 20-6
CLARIFIED QUESTION: Where can developers find details about which GNP and CFR provisions are waived during an emergency?
CLARIFIED ANSWER: Developers can find details about waived GNP and CFR provisions during an emergency by reviewing the decision statements on the FDA Authorization Page.
VERBATIM QUESTION: Where can developers find details about which GNP and CFR provisions are waived during an emergency?
VERBATIM ANSWER: If you look at any of the decision statements on our FDA Authorization Page you will see what provisions are waived. I don't have them off the top of my head but if you look at those you will see what provision of GNP and CFRs are waived in an emergency situation. And if that doesn't address your question well enough you can come back to our EUA templates address and we'll answer any further questions.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: GNP and CFR waivers, FDA EUA provisions
REVIEW FLAG: False

QA Block 20-7
CLARIFIED QUESTION: How can developers submit follow-up questions to the FDA if their concerns about GNP requirements are not fully addressed by existing resources?
CLARIFIED ANSWER: Developers can consult the FDA Authorization Page for GNP provisions waived under EUA. If further clarity is needed, they can submit additional questions to the FDA through the EUA templates address.
VERBATIM QUESTION: How can developers submit follow-up questions to the FDA if their concerns about GNP requirements are not fully addressed by existing resources?
VERBATIM ANSWER: If you look at any of the decision statements on our FDA Authorization Page you will see what provisions are waived. I don't have them off the top of my head but if you look at those you will see what provision of GNP and CFRs are waived in an emergency situation. And if that doesn't address your question well enough you can come back to our EUA templates address and we'll answer any further questions.
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: GNP requirements, EUA follow-up questions
REVIEW FLAG: False

QA Block 20-8
CLARIFIED QUESTION: What is the FDA's policy on publicly sharing information about entities willing to transfer serology test materials?
CLARIFIED ANSWER: The FDA does not publicly share information about entities willing to transfer serology test materials because such materials are usually proprietary. However, publicly available announcements by such entities can be referenced independently.
VERBATIM QUESTION: What is the FDA's policy on publicly sharing information about entities willing to transfer serology test materials?
VERBATIM ANSWER: So I know that we are trying to obtain some of those for our own internal interagency work but at this time we don't have plans to distribute that. Those are usually proprietary. I know that there is at least one entity out there that is publicly announced that they are willing to transfer their serology tests to others so you can certainly look at those public announcements and reach out to them. And if you - and I don't want to publicly state their names just because I want to be fair to everybody so okay?
SPEAKER QUESTION: James
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test materials, FDA policy on public information, proprietary sources
REVIEW FLAG: False

QA Block 20-9
CLARIFIED QUESTION: When will the transcript and presentation from this Town Hall be accessible on the CDRH Learn webpage?
CLARIFIED ANSWER: The presentation and transcript will be available on the CDRH Learn webpage by Monday, April 13.
VERBATIM QUESTION: When will the transcript and presentation from this Town Hall be accessible on the CDRH Learn webpage?
VERBATIM ANSWER: Today's presentation and transcript will be made available on the CDRH Learn Web page at www.fda.gov/training/cdrhlearn by Monday, April 13.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Irene Aihie (FDA Moderator)
TOPICS: Transcript availability, CDRH Learn webpage, Town Hall presentation
REVIEW FLAG: False

QA Block 20-10
CLARIFIED QUESTION: What is the procedure for providing feedback via the FDA CDRH Virtual Town Hall survey?
CLARIFIED ANSWER: Participants can provide feedback on their FDA CDRH Virtual Town Hall experience by completing a short 13-question survey, available at www.fda.gov/cdrhwebinar after the live discussion concludes.
VERBATIM QUESTION: What is the procedure for providing feedback via the FDA CDRH Virtual Town Hall survey?
VERBATIM ANSWER: Following the conclusion of today's presentation please complete a short 13 question survey about your FDA CDRH Virtual Town Hall experience. The survey can be found at www.fda.gov/cdrhwebinar immediately following the conclusion of today's live discussion.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Irene Aihie (FDA Moderator)
TOPICS: FDA CDRH survey, Feedback procedure
REVIEW FLAG: False

### removed qa blocks
QA Block 1-2
CLARIFIED QUESTION: Do laboratories need to submit validation data to the FDA when using alternate reagents or supplies?
CLARIFIED ANSWER: Laboratories using alternate reagents or supplies are not required to submit validation data to the FDA but are encouraged to do so for inclusion on the FDA FAQ page.
VERBATIM QUESTION: Do laboratories need to submit validation data to the FDA when using alternate reagents or supplies?
VERBATIM ANSWER: If you are a holder of an EUA authorization or have submitted an EUA and you're a laboratory you can simply do a bridging study with the alternate reagent or supply validate it to your standards into clear standards and then you can begin using that. You do not need to submit an amendment or an application to the FDA. If you are using someone else's EUA authorized device you could do the same thing without submitting if you're a laboratory submit - and submit that you don't have to if you're a laboratory you don't need to submit anything to the FDA. However in both situations we would love to see the validation instrument validation data that you generated in order that it might be helpful to others and with your position would like to add that alternate supplier reagent on to our Frequently Asked questions page. So it's not required to submit your data but we would love to see it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA requirements, Validation data, Alternate reagents
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: Which states are authorized to review tests, and where should validation data be sent?
CLARIFIED ANSWER: The six states authorized to review tests are Connecticut, Maryland, Mississippi, Nevada, New York, and Washington. Validation data can be sent either to the state or the FDA, but EUA applications to the FDA are always welcome even if a state authorizes testing.
VERBATIM QUESTION: Which states are authorized to review tests, and where should validation data be sent?
VERBATIM ANSWER: You can check our Frequently Asked Questions page for an update but currently as far as I know there are six states Connecticut, Maryland, Mississippi, Nevada New York and Washington State and then there is a question about whether validation should be sent to the state or to the FDA. Of course even if your state is willing to authorize tests within your state you are always welcome to submit an EUA application to the FDA.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: State authorization for test review, Validation data submission
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What guidance is available for designing and producing 3-D printed devices or other devices manufactured through nontraditional methods?
CLARIFIED ANSWER: The FDA supports 3-D printed devices and other nontraditional manufacturing methods by partnering with other agencies to share data and coordinate medical product development. Relevant guidance, including for devices like PPE and respirators, can be found on the FDA's website.
VERBATIM QUESTION: What guidance is available for designing and producing 3-D printed devices or other devices manufactured through nontraditional methods?
VERBATIM ANSWER: FDA has recognized that many stakeholders are interested in designing and producing 3-D printer devices and other types of and devices that are made through other nontraditional manufacturing methods as well. So what we have done to try to accept different input from the community is form a partnership under an MOU with the Department of Veterans Affairs innovation ecosystem and the NIH 3-D print exchange to share data and coordinate on open source medical products for the COVID-19 response. So these agencies were working with closely as well with American made supervise resources that will help connect healthcare providers and 3-D printing organizations. So we already have an FDA Q&A that's available on our Web site for 3-D printed medical devices including PPE, decontamination and reuse of respirators information, optimizing respirator decontamination and so on and so forth. So I would point you to our Web site for additional information on engaging us and our sister agencies on those efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3-D printed medical devices, Nontraditional manufacturing, FDA guidance
REVIEW FLAG: False

QA Block 1-20
CLARIFIED QUESTION: What are the FDA's expectations for validating the shipping and return of home collection samples to avoid false negatives?
CLARIFIED ANSWER: The FDA requires EUA authorization for home collection and home testing. They will work with developers to design studies ensuring home collection safety, sample accuracy during shipping, and validation measures to avoid false negatives.
VERBATIM QUESTION: What are the FDA's expectations for validating the shipping and return of home collection samples to avoid false negatives?
VERBATIM ANSWER: Next set of questions that are recurring have to do with whether or not home collection is allowed and we have said that collection and/or home testing require a UA authorization. So if you are interested in this pathway please reach out to us at our general EUA address and we'll work with you to design the appropriate studies to ensure that home collection is safe and is accurate and that the shipping return to the laboratory is also considered and is validated so that we know that when the samples are returned to the laboratory accurate results are obtained and false negatives are avoided. So we do welcome these. We do encourage these however we have stated that any EUA authorization is required.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home sample collection, Validation for false negatives, EUA authorization
REVIEW FLAG: False

QA Block 1-21
CLARIFIED QUESTION: What are the roles of the Department of Veterans Affairs and the NIH in the joint efforts for 3-D printing and additive manufacturing for medical products?
CLARIFIED ANSWER: The FDA, in partnership with the Department of Veterans Affairs and the NIH 3-D print exchange, is sharing data and coordinating on open-source medical products to support the COVID-19 response. This effort includes leveraging American-made supervised resources to connect healthcare providers and 3-D printing organizations.
VERBATIM QUESTION: What are the roles of the Department of Veterans Affairs and the NIH in the joint efforts for 3-D printing and additive manufacturing for medical products?
VERBATIM ANSWER: FDA has recognized that many stakeholders are interested in designing and producing 3-D printer devices and other types of and devices that are made through other nontraditional manufacturing methods as well. So what we have done to try to accept different input from the community is form a partnership under an MOU with the Department of Veterans Affairs innovation ecosystem and the NIH 3-D print exchange to share data and coordinate on open source medical products for the COVID-19 response. So these agencies were working with closely as well with American made supervise resources that will help connect healthcare providers and 3-D printing organizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3-D printing, COVID-19 response, Interagency collaboration
REVIEW FLAG: False

QA Block 1-22
CLARIFIED QUESTION: What resources are available to developers and healthcare providers for implementing 3-D printed and nontraditional manufacturing devices?
CLARIFIED ANSWER: FDA provides resources for 3-D printing and nontraditional manufacturing, including partnerships with the Department of Veterans Affairs and NIH for data sharing and coordination on open-source medical products. Additional information is available through FDA's website, including a Q&A on 3-D printed medical devices and related topics.
VERBATIM QUESTION: What resources are available to developers and healthcare providers for implementing 3-D printed and nontraditional manufacturing devices?
VERBATIM ANSWER: FDA has recognized that many stakeholders are interested in designing and producing 3-D printer devices and other types of and devices that are made through other nontraditional manufacturing methods as well. So what we have done to try to accept different input from the community is form a partnership under an MOU with the Department of Veterans Affairs innovation ecosystem and the NIH 3-D print exchange to share data and coordinate on open source medical products for the COVID-19 response. So these agencies were working with closely as well with American made supervise resources that will help connect healthcare providers and 3-D printing organizations. So we already have an FDA Q&A that's available on our Web site for 3-D printed medical devices including PPE, decontamination and reuse of respirators information, optimizing respirator decontamination and so on and so forth. So I would point you to our Web site for additional information on engaging us and our sister agencies on those efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3-D printing resources, nontraditional manufacturing, FDA partnerships
REVIEW FLAG: False

QA Block 1-23
CLARIFIED QUESTION: How can universities and academic institutions coordinate with the FDA to address supply shortages during public health emergencies?
CLARIFIED ANSWER: The FDA has engaged in dialogue with academic associations to collectively address local and national supply shortages through coordination of expertise and resources.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Also on a related note we've been made aware that there is a growing number of institutions from academic sector including universities and academic medical centers who are interested in contributing personnel expertise, resources and other things at their disposal across the country to try to address both local and national shortages. So we've engaged in dialogue at this point with the AAMCA AAU and APLU with regards to how we can all work together collectively across the university system as well to help address emerging challenges.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: University coordination, Supply shortages, Public health emergencies
REVIEW FLAG: False

QA Block 1-24
CLARIFIED QUESTION: What is the expected timeline for engaging with the FDA on 3-D printing or additive manufacturing-related efforts?
CLARIFIED ANSWER: The FDA collaborates with various agencies and provides resources on its website to support engagement in 3-D printing and additive manufacturing efforts for COVID-19. This includes partnerships to share data and coordinate on open source medical products.
VERBATIM QUESTION: What is the expected timeline for engaging with the FDA on 3-D printing or additive manufacturing-related efforts?
VERBATIM ANSWER: FDA has recognized that many stakeholders are interested in designing and producing 3-D printer devices and other types of and devices that are made through other nontraditional manufacturing methods as well. So what we have done to try to accept different input from the community is form a partnership under an MOU with the Department of Veterans Affairs innovation ecosystem and the NIH 3-D print exchange to share data and coordinate on open source medical products for the COVID-19 response. So these agencies were working with closely as well with American made supervise resources that will help connect healthcare providers and 3-D printing organizations. So we already have an FDA Q&A that's available on our Web site for 3-D printed medical devices including PPE, decontamination and reuse of respirators information, optimizing respirator decontamination and so on and so forth. So I would point you to our Web site for additional information on engaging us and our sister agencies on those efforts.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Sara Brenner (FDA)
TOPICS: 3-D printing, Additive manufacturing, FDA engagement
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Does the FDA post information on molecular diagnostic tests that have notified under Policy C?
CLARIFIED ANSWER: The FDA is listing molecular diagnostic tests that have notified under Policy C. If any are missing, contact the FDA via the EUA template to request their inclusion.
VERBATIM QUESTION: Does the FDA post information on molecular diagnostic tests that have notified under Policy C?
VERBATIM ANSWER: Yes, and we're listing those. So if we have not listed them yet please ping us at the EUA template and ask for them to be listed.
SPEAKER QUESTION: Nikki
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA listing of tests, Policy C notifications
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: What should a company do if their test is not listed on the relevant FAQ page despite notifying the FDA under Policy C?
CLARIFIED ANSWER: If a test is not listed on the relevant FAQ page despite notifying under Policy C, contact the FDA via the EUA template to request listing.
VERBATIM QUESTION: What should a company do if their test is not listed on the relevant FAQ page despite notifying the FDA under Policy C?
VERBATIM ANSWER: Yes, and we're listing those. So if we have not listed them yet please ping us at the EUA template and ask for them to be listed.
SPEAKER QUESTION: Nikki
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy C FAQ listings, EUA template communication
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Should molecular diagnostic tests notified under Policy C be listed on the FDA's FAQ page for tests under review?
CLARIFIED ANSWER: Molecular diagnostic tests notified under Policy C should be listed on the FDA's FAQ page. If they are missing, contact the EUA template team to get them listed.
VERBATIM QUESTION: Should molecular diagnostic tests notified under Policy C be listed on the FDA's FAQ page for tests under review?
VERBATIM ANSWER: Yes, and we're listing those. So if we have not listed them yet please ping us at the EUA template and ask for them to be listed.
SPEAKER QUESTION: Nikki
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Policy C tests, FAQ listings, Diagnostic test procedures
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: How does the FDA work with states to decide on the authorization of tests for home use?
CLARIFIED ANSWER: The FDA collaborates with states that can authorize tests for home use and asks developers of home-use tests to contact the FDA. If a state is willing to act, the FDA coordinates with it to make a decision.
VERBATIM QUESTION: How does the FDA work with states to decide on the authorization of tests for home use?
VERBATIM ANSWER: We of course are working with states who are able to authorize tests and we will reach out to New York about that. But we would ask that developers of home use test that they reach out to the FDA. And then if there's something that a state may be willing to do we can interact with that state to make a decision.
SPEAKER QUESTION: Peggy McLaughlin
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home-use test authorization, FDA collaboration with states
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: How will FDA clarify contradictory information regarding test complexity on its FAQ page?
CLARIFIED ANSWER: FDA will address and resolve the contradictory information about test complexity on its FAQ page to reduce confusion.
VERBATIM QUESTION: How will FDA clarify contradictory information regarding test complexity on its FAQ page?
VERBATIM ANSWER: I agree. We'll try to resolve the confusion on that Web site.
SPEAKER QUESTION: Franco Calderon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: contradictory FAQ information, test complexity, FDA clarification
REVIEW FLAG: False

QA Block 17-6
CLARIFIED QUESTION: What are the specific requirements for a home-based serology test to gain EUA authorization?
CLARIFIED ANSWER: The FDA is open to authorizing home-based serology tests, but the key requirements include ease of use for untrained patients, readability of test results, interpretation accuracy, and overall safety.
VERBATIM QUESTION: What are the specific requirements for a home-based serology test to gain EUA authorization?
VERBATIM ANSWER: We are very open to a home-based serology test. The important factors are, you know, how easy for this a patient, untrained patient to perform the testing? How easy is it to them to read the test results and how easy is it for them to interpret those results? Now for a typical rapid serology test there's questions in each of those places and also we do look at safety.
SPEAKER QUESTION: Ethan
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home-based serology tests, EUA requirements, FDA criteria
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2024-12-31 12:34:53 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 20
##### Explicit Questions Extraction
QE 1-1: Are developers required to validate alternate supplies and reagents such as alternate viral transport media, swabs, or PCR instruments?
QE 1-2: Do laboratories need to submit validation data to the FDA when using alternate reagents or supplies?
QE 1-3: What is required from test manufacturers when they make alterations to their products?
QE 1-4: Is home collection or home testing allowed, and what is necessary to pursue this pathway?
QE 1-5: Who can laboratories or developers contact regarding the design of studies for home collection to ensure safety and accuracy?
QE 1-6: How soon can developers expect to hear back after submitting an EUA application?
QE 1-7: Which states are authorized to review tests, and where should validation data be sent?
QE 1-8: Should validation data be sent to the authorized state or to the FDA if a state is reviewing the tests?
QE 1-9: What guidance is available for designing and producing 3-D printed devices or other devices manufactured through nontraditional methods?
QE 1-10: What information or organizations are involved in the FDA partnership for 3-D printing and additive manufacturing efforts to address supply chain issues?
QE 1-11: How can academic institutions contribute to addressing both local and national shortages?

##### Implicit Questions Extraction
QI 1-1: What are the specific accuracy concerns associated with serology tests, and how does the FDA plan to address them?
QI 1-2: How can developers participate in the voluntary interagency accuracy verification program for serology tests?
QI 1-3: What is the process for notifying the FDA about completing validation for serology tests under Pathway D?
QI 1-4: What type of data should developers provide to the FDA when voluntarily submitting validation data for alternate reagents or supplies?
QI 1-5: Are developers required to use a specific format when submitting validation data to the FDA?
QI 1-6: What is the FDA's process for independent assessment of the performance of serology tests?
QI 1-7: Does participation in the voluntary interagency program for accuracy testing have any impact on EUA applications or market authorization?
QI 1-8: When will the FDA provide additional updates regarding approvals for home collection and home testing pathways?
QI 1-9: What are the FDA's expectations for validating the shipping and return of home collection samples to avoid false negatives?
QI 1-10: What are the roles of the Department of Veterans Affairs and the NIH in the joint efforts for 3-D printing and additive manufacturing for medical products?
QI 1-11: What resources are available to developers and healthcare providers for implementing 3-D printed and nontraditional manufacturing devices?
QI 1-12: How can universities and academic institutions coordinate with the FDA to address supply shortages during public health emergencies?
QI 1-13: What is the expected timeline for engaging with the FDA on 3-D printing or additive manufacturing-related efforts?

#### Section 2 of 20
##### Explicit Questions Extraction
QE 2-1: Should a manufacturer using Policy C for EUA of a serology kit with incomplete initial validation data engage in pre-EUA conversations with the FDA to understand additional data requirements?

##### Implicit Questions Extraction
QI 2-1: What is the process for obtaining a fact sheet for submissions under Policy C?
QI 2-2: Can a submission with incomplete initial validation data proceed without pre-EUA discussions?
QI 2-3: Which pathway, pre-EUA or direct submission, does the FDA recommend for a more efficient review process?

#### Section 3 of 20
##### Explicit Questions Extraction
QE 3-1: If we are looking at alternate sample types, will a bridging study suffice or do we need to design an appropriate study with FDA guidance?

##### Implicit Questions Extraction
QI 3-1: What is the complete list of sample types currently authorized by the FDA for COVID-19 diagnostic tests?
QI 3-2: Does the FDA require engagement with developers for alternate sample types that are not already authorized?
QI 3-3: What kind of data has the FDA reviewed regarding tongue swabs and saliva as alternate sample types?
QI 3-4: Can developers perform their own bridging study for switching swabs, and under what circumstances is this permissible?
QI 3-5: Is submission to the FDA required if an EUA-authorized test is altered using a different sample type?
QI 3-6: What is the FDA's process for authorizing home collection or home testing for EUA platforms?

#### Section 4 of 20
##### Explicit Questions Extraction
QE 4-1: Do CLIA laboratories need to utilize research-use-only (RUO) components for the development of their assays?
QE 4-2: Does the guidance on RUO components also apply to manufacturers and specifically to instruments?
QE 4-3: Is it possible for kit manufacturers to develop kits for use with RUO instruments?
QE 4-4: Would manufacturers be able to develop a test and make it available while issuing an EUA within 15 days?
QE 4-5: Would the FDA prefer to engage with manufacturers before an EUA issuance?

##### Implicit Questions Extraction
QI 4-1: Under the emergency authorization program, what validations are required for RUO instruments to be used with assays?
QI 4-2: What challenges might developers face when the EUA comes to an end, particularly regarding the use of RUO components?
QI 4-3: What are the pathways for transitioning RUO instruments to full authorization after the cessation of the emergency declaration?
QI 4-4: Does the FDA recommend developers prepare for full submission requirements for test components or instruments once the EUA ends?
QI 4-5: Are there specific provisions for technologies transitioning from EUA to traditional authorization pathways, such as de novo or 510(k) submissions?

#### Section 5 of 20
##### Explicit Questions Extraction
QE 5-1: Can serology tests be used in labs with moderate complexity and a certificate under FDA guidance?
QE 5-2: When will the template for EUA serology tests be available?

##### Implicit Questions Extraction
QI 5-1: What steps can a developer take to get their point-of-care serology test deemed as moderately complex or waived?
QI 5-2: Does the FDA have any alternative pathways under evaluation to address the classification and use of serology tests in non-high complexity settings?
QI 5-3: How can developers participate in the interagency effort to verify the performance of serology tests?
QI 5-4: What implications does the CMS opinion have for the regulatory process of serology tests in high complexity labs?
QI 5-5: Is it possible to expedite the EUA authorization process for point-of-care tests designed for non-high complexity settings?
QI 5-6: What specific performance measures or standards are being evaluated in the FDA's voluntary serology test verification program?

#### Section 6 of 20
##### Explicit Questions Extraction
QE 6-1: What is the best way for lab professionals in the industry to get involved in assisting with COVID-19 test selection, test validations, and electronic reporting?
QE 6-2: Is there a portal for industry professionals who want to get involved in COVID-19 efforts?

##### Implicit Questions Extraction

#### Section 7 of 20
##### Explicit Questions Extraction
QE 7-1: What is the applicability and validity of current COVID-19 tests, such as nasopharyngeal or serology tests, for use on deceased patients, given that none of the kits have cateveric indications for use?

##### Implicit Questions Extraction
QI 7-1: What is the process for labs using an EUA-authorized device to validate an application for deceased patient testing without FDA submission?
QI 7-2: Can laboratories perform bridging studies or other validations on their own authority for specific applications outside the original authorization scope?
QI 7-3: Has the FDA authorized any COVID-19 tests for deceased patient applications similar to the Ebola test authorization?
QI 7-4: If guidance is needed for using COVID-19 tests on deceased patients, where should developers or labs direct such questions?

#### Section 8 of 20
##### Explicit Questions Extraction
QE 8-1: Does the EUA pathway under Policy D allow a serology test to be a quantitative test, or do we have to submit a 510(k) to make it a quantitative test?
QE 8-2: Is the FDA currently not reviewing quantitative tests?

##### Implicit Questions Extraction
QI 8-1: Is it possible to obtain FDA authorization for a serology test measuring IgG and IgM quantitatively under Pathway D?
QI 8-2: What steps should a developer take to resolve discrepancies or miscommunications regarding the review process for quantitative tests?
QI 8-3: Who should developers contact within the FDA if a submitted inquiry requires escalation or verification?
QI 8-4: How does the FDA plan to share clarification about quantitative test authorization more broadly with concerned stakeholders?

#### Section 9 of 20
##### Explicit Questions Extraction
QE 9-1: Are laboratories that are validating commercially available tests expected to perform antibody class specificity studies for serological testing, or is that an expectation of the manufacturer?

##### Implicit Questions Extraction

#### Section 10 of 20
##### Explicit Questions Extraction
QE 10-1: When a company notifies the FDA under Policy C of their intent to distribute a test while their EUA is being reviewed, should the company appear on the associated FAQ page?
QE 10-2: Does the FDA post information on molecular diagnostic tests that have notified under Policy C?
QE 10-3: What should a company do if their test is not listed on the relevant FAQ page despite notifying the FDA under Policy C?

##### Implicit Questions Extraction
QI 10-1: Should molecular diagnostic tests notified under Policy C be listed on the FDA's FAQ page for tests under review?
QI 10-2: If a molecular test is not listed on the FDA's FAQ page under Policy C, can developers contact the FDA via the EUA template to request listing?

#### Section 11 of 20
##### Explicit Questions Extraction
QE 11-1: Can states authorize home use serology tests that have not received an EUA?
QE 11-2: Is it allowed for a company to create test kits for home collection that are then shipped back to the company for testing?

##### Implicit Questions Extraction
QI 11-1: What steps does the FDA expect developers of home use serology tests to take before reaching out to states?
QI 11-2: How does the FDA work with states to decide on the authorization of tests for home use?
QI 11-3: What is the FDA's process when a state expresses interest in authorizing a diagnostic test that involves home collection?

#### Section 12 of 20
##### Explicit Questions Extraction
QE 12-1: Will there be any type of notification to alert doctors' offices that serology test kits are not being used in the proper settings?
QE 12-2: Is it possible for third-party approvals or reviews to be used for submissions of serology tests?

##### Implicit Questions Extraction
QI 12-1: How will FDA clarify contradictory information regarding test complexity on its FAQ page?
QI 12-2: Are there plans to update the FDA website to make information about test complexity clearer?
QI 12-3: What steps should developers take if they encounter contradictory guidance on FDA resources?
QI 12-4: Can developers reach out to the FDA through email to address confusion regarding test complexity designations?

#### Section 13 of 20
##### Explicit Questions Extraction
QE 13-1: Do you have data or bridging studies to show the superiority of phosphate buffered saline (PBS) over normal saline?
QE 13-2: Do you have a specific formulation of phosphate buffered saline (PBS) that you're recommending?

##### Implicit Questions Extraction

#### Section 14 of 20
##### Explicit Questions Extraction
QE 14-1: If two subsidiaries of the same parent company want to market the same or similar COVID-19 test, do both need to file an EUA followed by a 510K, or does only one need to file?
QE 14-2: If one of the tests is manufactured in the US and the other outside the US with different manufacturing sites and raw material sources, does this make it a different product for EUA filing purposes?
QE 14-3: Do the rules that allow only one 510K for the same product apply to EUA filings if the manufacturing sites and raw material sources are different?

##### Implicit Questions Extraction
QI 14-1: What is the FDA's protocol for listing two separate manufacturers in an EUA submission?
QI 14-2: Can an entity reference another entity's data package to file a separate or 'shell' EUA?
QI 14-3: How is the legal manufacturer determined when the same test is produced at separate manufacturing sites?

#### Section 15 of 20
##### Explicit Questions Extraction
QE 15-1: If a test kit is under the notification arm, can it only be used in laboratories?
QE 15-2: Can a physician perform, interpret, and use the test for the patient without being associated with a laboratory certified as moderate or high complexity?
QE 15-3: Is it true that capillary blood finger sticks are not allowed?
QE 15-4: Is it stated explicitly anywhere, such as in bold type, that finger sticks cannot be used?

##### Implicit Questions Extraction
QI 15-1: What is the significance of the CMS requirement for a CLIA waiver certificate, even for tests deemed CLIA waived, and how does it impact test deployment?
QI 15-2: Can capillary or finger-stick blood samples be used for serology tests in high-complexity laboratories, and what specific validations are required?
QI 15-3: Under what circumstances would the FDA deem a point-of-care serology test using finger-stick blood suitable for a CLIA-waived environment?

#### Section 16 of 20
##### Explicit Questions Extraction
QE 16-1: What is the FDA's stance on bringing in UTM from a foreign manufacturer that may not be listed or registered?
QE 16-2: Is there any kind of fast track process to get unauthorized UTM from a foreign manufacturer approved for use?

##### Implicit Questions Extraction

#### Section 17 of 20
##### Explicit Questions Extraction
QE 17-1: If we use serology tests at an appropriate site, will we be able to use telehealth for the physician consultation?
QE 17-2: Can serology tests not authorized under EUA be used for diagnosis?
QE 17-3: What are the requirements for a telehealth-based home serology test to be authorized by the FDA?

##### Implicit Questions Extraction
QI 17-1: What are the scientific challenges preventing serology tests from being authorized as the sole basis for diagnosis?
QI 17-2: Can the FDA provide details on what would be required to pursue authorization of a serology test for sole diagnostic use?
QI 17-3: What are the specific requirements for a home-based serology test to gain EUA authorization?
QI 17-4: What factors does the FDA consider when evaluating the safety of home-based serology tests?
QI 17-5: Is a video link considered sufficient support for patients conducting serology tests at home?

#### Section 18 of 20
##### Explicit Questions Extraction
QE 18-1: Is the panel of positive and negative plasma something that serology assay developers will have access to, or is it just for FDA to test submitted kits?

##### Implicit Questions Extraction
QI 18-1: What is the procedure for volunteering to participate in the central lab testing program?
QI 18-2: How can developers ensure they will be informed if panels become available for shipment?
QI 18-3: What agencies are involved in the interagency program collaboration?
QI 18-4: Will the remaining plasma/sera be prioritized for specific types of serology assay development?
QI 18-5: Are there any criteria to qualify for participation in the interagency program?

#### Section 19 of 20
##### Explicit Questions Extraction
QE 19-1: What should we do if companies sold serology test kits in Puerto Rico before notifying the FDA, and clinical labs issued reports based on these tests?
QE 19-2: Should we inform patients that their reports may be invalid if serology tests were commercialized before FDA notification?
QE 19-3: Can the exact date that each company was allowed to commercialize their serology tests be published on a website?
QE 19-4: Should we take action if serology test kits were sold before notification but the issue lies with the distributors, not the manufacturers?

##### Implicit Questions Extraction

#### Section 20 of 20
##### Explicit Questions Extraction
QE 20-1: What does the waiver of GNP requirements under an EUA mean?
QE 20-2: Will further guidance be issued regarding GNP requirement waivers under an EUA?
QE 20-3: Do you have sources for bulk COVID-19 protein antigen for the serology test?
QE 20-4: Are government agencies pursuing efforts for bulk COVID-19 protein antigen in partnership with private entities?

##### Implicit Questions Extraction
QI 20-1: What specific complaint handling and adverse event reporting requirements must be retained if GNP requirements are waived under an EUA?
QI 20-2: Where can developers find details about which GNP and CFR provisions are waived during an emergency?
QI 20-3: How can developers submit follow-up questions to the FDA if their concerns about GNP requirements are not fully addressed by existing resources?
QI 20-4: What is the FDA's policy on publicly sharing information about entities willing to transfer serology test materials?
QI 20-5: When will the transcript and presentation from this Town Hall be accessible on the CDRH Learn webpage?
QI 20-6: What is the procedure for providing feedback via the FDA CDRH Virtual Town Hall survey?
